0001161697-19-000477.txt : 20191106 0001161697-19-000477.hdr.sgml : 20191106 20191106162246 ACCESSION NUMBER: 0001161697-19-000477 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191106 DATE AS OF CHANGE: 20191106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPRO MED SYSTEMS INC CENTRAL INDEX KEY: 0000704440 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133044880 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39086 FILM NUMBER: 191196622 BUSINESS ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 BUSINESS PHONE: 845-469-2042 MAIL ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 10-Q 1 form_10-q.htm FORM 10-Q QUARTERLY REPORT FOR 09-30-2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File Number: 0-12305

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


New York	13-3044880
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

24 Carpenter Road, Chester, New York	10918
(Address of Principal Executive Offices)	(Zip Code)

(845) 469-2042

(Registrant’s telephone number, including area code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
common stock, $0.01 par value	KRMD	The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


	Large accelerated filer [ ]	Accelerated filer [ ]
	Non-accelerated filer [ ]	Smaller reporting company [X]
		Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of November 6, 2019, 39,501,870 shares of common stock, $0.01 par value per share, were outstanding, which excludes 2,737,231 shares of treasury stock.

REPRO MED SYSTEMS, INC.

TABLE OF CONTENTS


		PAGE

PART I – FINANCIAL INFORMATION

ITEM 1.	Financial Statements

	Balance Sheets as of September 30, 2019 (Unaudited) and December 31, 2018	3

	Statements of Operations (Unaudited) for the three and nine months ended September 30, 2019 and 2018	4

	Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2019 and 2018	5

	Notes to Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	22

ITEM 4.	Controls and Procedures	22

PART II – OTHER INFORMATION

ITEM 1.	Legal Proceedings	22

ITEM 1A.	Risk Factors	24

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

ITEM 6.	Exhibits	25

- 2 -

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

REPRO MED SYSTEMS, INC.

BALANCE SHEETS


	September 30,
	2019			December 31,
	(Unaudited)			2018
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	5,129,028		$	3,738,803
Certificates of deposit		—			1,517,927
Accounts receivable less allowance for doubtful accounts of $36,609 at September 30, 2019 and $37,500 at December 31, 2018		3,546,634			1,425,854
Inventory		2,738,682			2,103,879
Prepaid expenses		453,151			246,591
TOTAL CURRENT ASSETS		11,867,495			9,033,054
Property and equipment, net		636,928			858,781
Patents, net of accumulated amortization of $273,846 and $239,581 at September 30, 2019 and December 31, 2018, respectively		786,164			632,156
Right of use assets, net		406,954			—
Deferred tax asset		—			1,466
Other assets		19,582			19,582
TOTAL ASSETS	$	13,717,123		$	10,545,039

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Deferred capital gain - current	$	—		$	3,763
Accounts payable		874,977			453,498
Accrued expenses		1,178,702			688,649
Accrued payroll and related taxes		111,359			421,714
Accrued tax liability		—			16,608
Finance lease liability - current		3,242			—
Operating lease liability - current		135,275			—
TOTAL CURRENT LIABILITIES		2,303,555			1,584,232
Deferred tax liability		133,097			—
Operating lease liability, net of current portion		271,679			—
TOTAL LIABILITIES		2,708,331			1,584,232

STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 42,228,658 and 40,932,911 shares issued, 39,491,427 and 38,195,680 shares outstanding at September 30, 2019 and December 31, 2018, respectively		422,286			409,329
Additional paid-in capital		5,985,636			4,595,214
Retained earnings		4,945,074			4,300,468
		11,352,996			9,305,011
Less: Treasury stock, 2,737,231 shares at September 30, 2019 and December 31, 2018, respectively, at cost		(344,204	)		(344,204	)
TOTAL STOCKHOLDERS’ EQUITY		11,008,792			8,960,807
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	13,717,123		$	10,545,039

The accompanying notes are an integral part of these financial statements

- 3 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS (UNAUDITED)


	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2019			2018			2019			2018

NET SALES	$	6,617,397		$	4,547,187		$	16,940,487		$	13,082,737
Cost of goods sold		2,234,489			1,655,619			6,033,961			4,985,761
Gross Profit		4,382,908			2,891,568			10,906,526			8,096,976

OPERATING EXPENSES
Selling, general and administrative		2,441,381			1,917,127			6,976,684			5,513,727
Litigation		864,009			286,487			2,481,471			592,787
Research and development		170,260			126,923			450,454			160,735
Depreciation and amortization		82,774			78,345			252,594			228,900
Total Operating Expenses		3,558,424			2,408,882			10,161,203			6,496,149

Net Operating Profit		824,484			482,686			745,323			1,600,827

Non-Operating Income/(Expense)
Loss on currency exchange		(9,358	)		(5,842	)		(20,283	)		(16,256	)
Gain on disposal of fixed asset, net		—			6,000			49,740			6,000
Interest, net and other income, net		23,368			6,972			59,091			13,088
TOTAL OTHER INCOME		14,010			7,130			88,548			2,832

INCOME BEFORE TAXES		838,494			489,816			833,871			1,603,659

Income Tax Expense		(186,681	)		(103,263	)		(189,265	)		(337,956	)

NET INCOME	$	651,813		$	386,553		$	644,606		$	1,265,703

NET INCOME PER SHARE

Basic	$	0.02		$	0.01		$	0.02		$	0.03
Diluted	$	0.02		$	0.01		$	0.02		$	0.03

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic		39,022,298			38,194,682			38,534,021			38,104,393
Diluted		39,298,408			38,985,684			38,734,083			38,875,737

The accompanying notes are an integral part of these financial statements

- 4 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


	For the Nine Months Ended
	September 30,
	2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$	644,606		$	1,265,703
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Stock based compensation expense		897,300			154,925
Depreciation and amortization		252,594			228,900
Deferred capital gain - building lease		(3,763	)		(16,860	)
Deferred taxes		134,563			10,834
Gain on disposal of fixed asset		(49,740	)		(6,000	)
Changes in operating assets and liabilities:
(Increase)/Decrease in accounts receivable		(2,120,780	)		351,319
Increase in inventory		(634,803	)		(290,722	)
Increase in prepaid expense and other assets		(206,560	)		(177,346	)
Increase in accounts payable		421,479			137,521
Decrease in accrued payroll and related taxes		(310,355	)		(213,700	)
Increase/(Decrease) in accrued expense		490,053			(30,823	)
Decrease in accrued tax liability		(16,608	)		(60,852	)
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES		(502,014	)		1,352,899

CASH FLOWS FROM INVESTING ACTIVITIES
Payments for capital expenditures		(158,193	)		(188,006	)
Purchase of certificate of deposit		—			(1,500,000	)
Payments for patents		(188,274	)		(137,858	)
Proceeds on disposal of fixed asset		217,821			6,000
Proceeds from certificates of deposit		1,517,927			92,266
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES		1,389,281			(1,727,598	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuances		508,900			51,250
Payment for cancelled shares		(2,820	)		(1,755	)
Finance lease		(3,122	)		—
NET CASH PROVIDED BY FINANCING ACTIVITIES		502,958			49,495

NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS		1,390,225			(325,204	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		3,738,803			3,974,536
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	5,129,028		$	3,649,332

Supplemental Information
Cash paid during the periods for:
Interest	$	280		$	—
Taxes	$	103,465		$	378,000

NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$	256,525		$	103,333

The accompanying notes are an integral part of these financial statements

- 5 -

REPRO MED SYSTEMS, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

REPRO MED SYSTEMS, INC. (the “Company”, “KORU Medical” or “we”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management. The Company operates as one segment.

FISCAL YEAR END

The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION

The accompanying unaudited financial statements as of September 30, 2019, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.

In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of September 30, 2019, and the results of operations and cash flow for the three and nine month periods ended September 30, 2019, and 2018.

The results of operations for the nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the twelve months ended December 31, 2018, as filed with the Securities and Exchange Commission on Form 10-K.

CASH AND CASH EQUIVALENTS

For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.

CERTIFICATES OF DEPOSIT

The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019, at which time the funds were moved into a money market account earning interest at 2.25%. Effective September 24, 2019, the money market account interest rate dropped to 1.85%.

INVENTORY

Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.

PATENTS

Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.

- 6 -

INCOME TAXES

Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences.

The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2016 are subject to examination by income tax authorities.

PROPERTY, EQUIPMENT, AND DEPRECIATION

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.

STOCK-BASED COMPENSATION

The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

REVENUE RECOGNITION

The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted this ASU effective January 1, 2018 on a full retrospective basis. Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or related disclosures. As such, prior period financial statements were not recast.

The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs and at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales.

The Company generally does not accept return of goods shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred.

Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it’s probable the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers.

LEASES

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current U.S. GAAP, while our accounting for capital leases remains substantially unchanged. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard became effective for us January 1, 2019. The standard had a material impact on our balance sheets, but did not have a material impact on our income statements. See NOTE 7 LEASES.

- 7 -

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure for Fair Value Measurement. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. An entity is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In August 2018, the FASB issued ASU No. 2018-15 Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this ASU. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period, for all entities. The amendments in this ASU should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.

ACCOUNTING FOR LONG-LIVED ASSETS

The Company reviews its long-lived assets for impairment at least annually or whenever the circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. As of September 30, 2019, the Company does not believe that any of its assets are impaired.

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

- 8 -

NOTE 2 RELATED PARTY TRANSACTIONS

LEASED AIRCRAFT

From 1992 to 2018, we leased an aircraft from AMI Aviation, Inc., of which our former President and Chief Executive Officer, Andrew Sealfon, was a majority shareholder. The lease payments were zero and $1,292 for the three months ended September 30, 2019 and 2018, respectively and zero and $9,045 for the nine months ended September 30, 2019 and 2018 respectively. Upon the termination of Mr. Sealfon as President and Chief Executive Officer on July 25, 2018, the Company ceased leasing this aircraft.

BUILDING LEASE

Mr. Pastreich, a former director, is a principal in the entity that owns the building leased by us for our corporate headquarters and manufacturing facility at 24 Carpenter Road, Chester, New York 10918. On February 28, 2019, we completed year twenty of a twenty year lease with monthly lease payments of $11,042. On November 14, 2017, we executed a lease extension, which calls for six month extensions beginning March 1, 2019 with the option to renew six times at a monthly lease amount of $12,088. The Company exercised three additional renewal options commencing September 1, 2019 through February 28, 2021.

The lease payments were $36,264 and $33,126 for the three months ended September 30, 2019 and 2018, respectively, and $106,700 and $99,378 for the nine months ended September 30, 2019 and 2018, respectively. The Company also paid property taxes in the amount of $13,749 and $12,431 for the three months ended September 30, 2019 and 2018, respectively and $39,165 and $37,863 for the nine months ended September 30, 2019 and 2018, respectively.

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:


	September 30, 2019			December 31, 2018

Land	$	—		$	54,030
Building		—			171,094
Furniture, office equipment, and leasehold improvements		1,120,416			1,058,507
Manufacturing equipment and tooling		1,309,172			1,279,865
		2,429,588			2,563,496
Less: accumulated depreciation		(1,792,660	)		(1,704,715	)
Property and equipment, net	$	636,928		$	858,781

On May 21, 2019, the Company sold the house it owned for $0.2 million.

Depreciation expense was $69,740 and $68,991 for the three months ended September 30, 2019 and 2018, respectively, and $218,328 and $202,975 for the nine months ended September 30, 2019 and 2018, respectively.

NOTE 4 LEGAL PROCEEDINGS

We are involved in several lawsuits with our principal competitor, EMED Technologies Corporation (“EMED”). EMED has alleged that our needle sets infringe various patents controlled by EMED. Certain of these lawsuits also allege antitrust violations, unfair business practices, and various other business tort claims. We are vigorously defending against all of the lawsuits brought by EMED. Although no assurances can be given, we believe we have meritorious defenses to all of EMED’s claims.

- 9 -

The initial case involving EMED was filed by us in the United States District Court for the Eastern District of California on September 20, 2013 (the “California case”), in response to a letter from EMED claiming patent infringement by us, and seeking a declaratory judgment establishing the invalidity of the patent referenced in the letter – EMED’s US patent 8,500,703 – “‘703.” EMED answered the complaint and asserted patent infringement of the ‘703 patent and several counterclaims relating generally to claims of unfair business practices against us. We responded by adding several claims against EMED, generally relating to claims of unfair business practices on EMED’s part. Both parties have requested injunctive relief and monetary damages in unspecified amounts. On June 16, 2015, the California court entered a preliminary injunction against KORU Medical making certain statements regarding what products were cleared by the FDA for use, or could be safely used, with KORU Medical’s Freedom60 pump, without voiding the product warranty. On September 11, 2015, we requested an ex parte reexamination of the ‘703 patent by the US Patent and Trademark Office (“USPTO”). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017 rejecting all of EMED’s claims in the patent. On January 25, 2018, EMED filed an Appeal Brief with a Petition for Revival, which was accepted. On April 9, 2018, the USPTO denied EMED’s request for reconsideration of the order rejecting all claims in the ‘703 patent. On June 26, 2019, the Examiner responded to EMED’s appeal brief and maintained all of the final rejections. Both the California case and EMED’s appeal of the USPTO rejections are pending.

The second court case was filed by EMED in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement on another of its patents (US 8,961,476 – “‘476”), by our needle sets, and seeking unspecified monetary damages (“ED Texas ‘476 matter”). This ‘476 patent is related to the now rejected EMED ‘703 patent.

On September 17, 2015, we requested an inter partes review (“IPR”) of the ‘476 patent, and in response to our request, the Court entered an order staying the ED Texas ‘476 matter until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its Final Written Decision in our favor, invalidating all but one (“dependent Claim 9”) of the claims in the ‘476 patent. EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in our favor on April 3, 2018. On April 18, 2018, EMED filed a petition for en banc rehearing, which was denied. On August 16, 2018, EMED petitioned the United States Supreme Court for a Writ of Certiorari to review the Federal Circuit’s upholding the PTAB’s Final Written Decision. On October 29, 2018 the United States Supreme Court denied EMED’s Petition for a Writ of Certiorari, thus finally affirming the PTAB’s invalidation of ‘476, save for one dependent claim.

Following the PTAB’s Final Written Decision in the IPR regarding the ‘476 patent, EMED filed a new patent application claiming priority back to the application that issued as ‘703, which is the patent at issue in the California case. Submitted for accelerated examination, this new application issued as US 9,808,576 – “‘576” on November 7, 2017. On this same date, EMED filed a new case (the “third case”) in the United States District Court for the Eastern District of Texas claiming patent infringement of ‘576, also directed to our needle sets, and seeking unspecified damages and a preliminary injunction against marketing and sales of our needle sets. We filed a Motion to Dismiss or Transfer Venue to the United States District Court for the Southern District of New York (“SDNY”), which resulted in the transfer of the third case to SDNY (“SDNY ‘576 matter”) on May 30, 2018.

On April 23, 2018, EMED filed a new civil case (the “fourth case”) against us in the United States District Court for the Eastern District of Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the California case, described above. The fourth case also names Andrew Sealfon, then President and CEO of KORU Medical, individually as a defendant. As the result of a hearing on November 14, 2018, on December 7, 2018, the Court entered an order transferring the fourth case to the United States District Court for the Eastern District of California (the “California Court”). The California Court set an initial schedule for a preliminary motion phase and on August 30, 2019 EMED filed a second amended complaint. On September 30, 2019, KORU Medical and Sealfon filed a motion to dismiss that complaint, and Sealfon filed a separate motion to dismiss the case as to him for lack of jurisdiction. Ultimately, we expect this case to be coordinated or consolidated with the California case, or dismissed, as the California Court sees fit.

At the same hearing on November 14, 2018, the Texas Court granted EMED leave to amend its infringement contentions, following the IPR decision invalidating all but one claim of the ‘476 patent, in order to assert infringement of that sole remaining claim, namely dependent Claim 9. The Texas Court’s order allowing EMED’s amendment of its infringement contentions against us was entered on December 7, 2018.

- 10 -

The ED Texas ‘476 matter proceeded under EMED’s amended infringement contention to incorporate the surviving dependent Claim 9, which incorporates Claims 1 and 8 of the ‘476 patent, meaning that, to prove infringement on the part of us, EMED must prove more elements of infringement than it originally charged against us. In April 2019, EMED served its damages expert’s report opining that EMED’s past infringement damages amount to $1.5 million, and in May KORU Medical served its damages expert’s rebuttal report opining that EMED’s expert miscalculated damages which if properly calculated would amount to less than $100,000. The Texas Court had set a trial date of August 19, 2019, for the trial of the ED Texas ‘476 matter. On June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision finding no infringement, literally or under the doctrine of equivalents, by KORU Medical’s accused products. EMED filed its objections on June 26, 2019. On June 28, 2019 the United States District Judge for the Eastern District of Texas issued a Final Judgment in favor of KORU Medical and adopted the decision of the Magistrate Judge that was issued on June 24, 2019, overruled EMED’s objections, awarded court costs to KORU Medical, and dismissed the case. A final judgment has been entered. KORU Medical has submitted its Bill of Costs for approximately $16,000 and moved to declare the case exceptional and for recovery of its attorney fees and expenses of approximately $2.3 million in defense of EMED’s assertion of the ‘476 Patent. EMED has objected to our Bill of Costs, opposed the motion for fees, and filed a notice of appeal of the non-infringement judgment to the Court of Appeals for the Federal Circuit. On September 16, 2019, EMED filed its opening appeal brief. KORU Medical plans to oppose EMED’s appeal. The ED Texas court has stayed proceedings in the district court until the appeal process is completed. KORU Medical’s fee motion remains pending lifting of the stay.

The SDNY ‘576 matter proceeded in the New York court through claim construction on the ‘576 Patent, whereupon KORU Medical sought permission from the New York court to file a motion for summary judgement, to which EMED objected. The New York court granted KORU Medical’s request, and on July 10, 2019, KORU Medical filed its motion for summary judgement. EMED opposed that motion, and on August 30, 2019, the New York court granted summary judgement, and dismissed the lawsuit. A final judgement has been entered. KORU Medical has submitted a Bill of Costs for approximately $1,500, to which EMED has objected, and has moved the New York court to declare the case exceptional and for recovery of its attorney fees and expenses of at least $1.16 million. EMED has opposed that motion, which is now fully briefed and has been referred to a United States District Court Magistrate Judge to prepare a report and recommendation. EMED also has appealed the New York court’s judgment of non-infringement to the Court of Appeals of the Federal Circuit, which matter is pending. EMED’s opening appeal brief is currently due November 8, 2019.

As is required by the respective Courts in both the SDNY ‘576 matter and the ED Texas ‘476 matter, the parties are engaging in settlement discussions and have conducted a court-sponsored mediation session, which did not result in settlement.

Although we believe KORU Medical has meritorious claims and defenses in all of the above-described actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against us are successful, they could have a material adverse effect on our business, results of operations, financial condition and cash flows.

NOTE 5 STOCK-BASED COMPENSATION

On June 29, 2016, the Board of Directors amended the 2015 Stock Option Plan (as amended, the “Plan”) authorizing the Company to grant awards to certain executives, key employees, and consultants under the Plan, which was approved by shareholders at the Annual Meeting held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed 6,000,000 pursuant to an amendment to the Plan approved by shareholders on April 23, 2019 at the 2019 Annual Meeting of Shareholders.

As of September 30, 2019, the Company had 3,897,000 time based stock options outstanding to certain executives, key employees and consultants under the Plan, of which 1,650,000 were issued during the nine months ended September 30, 2019. The Company also had 1,000,000 performance based options outstanding under the Plan as of September 30, 2019, to its President and Chief Executive Officer, of which all were issued during the nine months ending September 30, 2019.

On February 20, 2019, the Board of Directors of the Company approved an increase in compensation for each non-employee director from $25,000 to $50,000 annually effective January 1, 2019 and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock at the end of each fiscal quarter.

Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000 to be paid half in cash and half in stock on April 1, 2019. The number of shares that were issued totaled 90,604 and was based upon the closing price of the Common Stock of the Company on February 1, 2019 as reported by the OTCQX. These shares were issued on April 3, 2019.

- 11 -

2015 STOCK OPTION PLAN, as amended

Time Based Stock Options

The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and September 30, 2018 was $1.33 and $0.68, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.


	September 30,
	2019		2018

Dividend yield		0.00%		0.00%
Expected Volatility		56.1 – 60.7%		62.8 – 65.2%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10 Years		5 Years
Risk-free rate		1.60 – 2.72%		2.80 – 2.90%

The following table summarizes the status of the Plan with respect to time based stock options:


	Nine months Ended September 30,
	2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	2,419,000	$	1.00		1,038,000	$	0.41
Granted	1,650,000	$	1.92		1,018,000	$	1.23
Exercised	160,000	$	0.37		125,000	$	0.41
Forfeited	12,000	$	0.87		12,000	$	0.87
Outstanding at September 30	3,897,000	$	1.41		1,919,000	$	0.85
Options exercisable at September 30	1,037,885	$	0.81		666,969	$	0.40
Weighted average fair value of options granted during the period	—	$	1.33		—	$	0.68
Stock-based compensation expense		$	473,139		—	$	51,592

Total stock-based compensation expense totaled $473,139 and $51,592 for the nine months ended September 30, 2019 and 2018, respectively. Cash received from option exercises for the nine months ended September 30, 2019 and 2018 was $58,900 and $51,250, respectively.

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and 2018, was $1.33 and $0.68, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2019 and 2018, was $30,022 and $30,664, respectively.

The following table presents information pertaining to options outstanding at September 30, 2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$ 0.38 – 3.15	3,897,000	7 years	$	1.41	1,037,885	$	0.81

- 12 -

As of September 30, 2019, there was $2,802,411 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 42 months. The total fair value of shares vested as of September 30, 2019 and 2018, was $506,729 and $139,569, respectively.

Performance Based Stock Options

The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and 2018 was $1.16 and zero, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.


	September 30,
	2019		2018

Dividend yield		0.00%		—
Expected Volatility		58.9%		—
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10 Years		—
Risk-free rate		2.07%		—

The following table summarizes the status of the Plan with respect to performance based stock options:


	Nine months Ended September 30,
	2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	—	$	—		—	$	—
Granted	1,000,000	$	1.70		—	$	—
Exercised	—	$	—		—	$	—
Forfeited	—	$	—		—	$	—
Outstanding at September 30	1,000,000	$	1.70		—	$	—
Options exercisable at September 30	—	$	—		—	$	—
Weighted average fair value of options granted during the period	—	$	1.16		—	$	—
Stock-based compensation expense	—	$	167,636		—	$	—

Total performance stock-based compensation expense totaled $167,636 and zero for the nine months ended September 30, 2019 and 2018, respectively.

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and September 30, 2018, was $1.16 and zero, respectively.

The following table presents information pertaining to performance based options outstanding at September 30, 2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.70	1,000,000	10 years	$	1.70	—	$	—

- 13 -

As of September 30, 2019, there was $994,925 of total unrecognized compensation cost related to non-vested performance share option based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 31 months. The total fair value of shares vested as of September 30, 2019 and 2018 was zero for both periods.

NOTE 6 DEBT OBLIGATIONS

On February 8, 2018, the Company issued a Promissory Note to KeyBank National Association (“KeyBank”) in the amount of $1.5 million as a variable rate revolving line of credit loan due on demand with an interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. The Company entered into this arrangement to establish a credit lending history and, in the event needed, to have additional cash on hand for future expansion. On September 25, 2018, KeyBank released the certificate of deposit as collateral for the loan and the Company executed a Commercial Security Agreement as collateral for the loan. As of September 30, 2019, the Company had no outstanding amounts against the line of credit.

NOTE 7 LEASES

We have finance and operating leases for our corporate office and certain office and computer equipment. Our leases have remaining lease terms of 1 to 3 years, some of which include options to extend the leases annually and some with options to terminate the leases within 1 year.

The components of lease expense were as follows:


	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019

Operating lease cost	$	37,922	$	111,672

Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	3,182
Interest on lease liabilities		47		178
Total finance lease cost	$	1,108	$	3,360

Supplemental cash flow information related to leases was as follows:


	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019

Cash paid for amounts included in the measurement of lease liabilities:
Finance cash flows from finance leases	$	1,053	$	3,122
Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	3,182
Interest on lease liabilities		47		178
Total finance lease cost	$	1,108	$	3,360

- 14 -

Supplemental balance sheet information related to leases was as follows:


	Nine Months Ended September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	406,954

Operating lease current liabilities		135,275
Operating lease long term liabilities		271,679
Total operating lease liabilities	$	406,954

Finance Leases
Property and equipment, at cost	$	6,363
Accumulated depreciation		3,182
Property and equipment, net	$	3,181

Finance lease current liabilities		3,242
Finance lease long term liabilities		—
Total finance lease liabilities	$	3,242


		Nine Months Ended September 30, 2019
Weighted Average Remaining Lease Term
Operating leases		3 Years
Finance leases		1 Year

Weighted Average Discount Rate
Operating leases		4.75%
Finance leases		4.75%

Maturities of lease liabilities are as follows:


Year Ending December 31,	Operating Leases			Finance Leases
2019	$	37,922		$	1,100
2020		151,685			2,206
2021		149,476			—
2022		97,256			—
Total lease payments		436,339			3,306
Less imputed interest		(29,385	)		(64	)
Total	$	406,954		$	3,242

NOTE 8 SUBSEQUENT EVENTS

On September 30, 2019, R. John Fletcher was appointed Chairman of the Board. Mr. Fletcher succeeds Daniel S. Goldberger who resigned as Executive Chairman of the Company in connection with his appointment as Chief Executive Officer of a bioelectronic medical device company. Mr. Goldberger remains with KORU Medical as a non-executive member of the Board of Directors. In Mr. Fletcher’s role as Chairman, he will receive an additional $50,000 in annual compensation, to be paid quarterly in shares of KORU Medical common stock based on the closing price of the stock on the last day of each quarter.

On October 14, 2019, KORU Medical announced that its common stock was approved for listing on The Nasdaq Capital Market and began trading on October 17, 2019 under its then current symbol “REPR”.

On October 23, 2019, the Company announced it will operate under a new dba name, KORU Medical Systems, in place of RMS Medical Products. Reflecting this change, the Company’s common stock commenced trading under the new ticker symbol “KRMD” effective October 24, 2019.

- 15 -

PART I – ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made and information currently available.

Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, expanding the market of FREEDOM60^®demand in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel, the impact of recent accounting pronouncements and the outcome of litigation. When used in this report, the words “estimate,” “project,” “believe,” “may,” “will,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Throughout this report, “KORU Medical,” the “Company,” “we,” “us” and “our” refer to Repro Med Systems, Inc.

OVERVIEW

The third quarter of 2019 ended with record net sales results of $6.6 million, an increase of 45.5% compared with the same period last year. The increase was driven by organic growth mostly from increased volume and to a lesser extent from price increases, two unusually large orders from a domestic distributor and a new customer in Europe, as well as clinical trials. The large domestic distributor orders followed the acquisition of Medical Specialties Distributors, LLC by McKesson Medical-Surgical, Inc. as they move forward with their integration. We cannot predict whether such large distributor orders or volume generally will continue in the future. We ended the third quarter with $0.8 million in open orders. Excluding the two large orders, clinical trials and adjusting for the open orders for the quarter, net sales grew in excess of 25% year over year. We believe the organic volume growth continues to be the result of growth in diagnosis of primary immunodeficiency diseases (“PIDD”) and expansion into the neurology market with expanded Hizentra® indication for chronic inflammatory demyelinating polyneuropathy (“CIDP”). Our gross margin percentage improved nearly 2.6 percentage points versus the same period last year mostly due to price increases. Net income was $0.7 million for period ended September 30, 2019, compared with $0.4 million for the previous year, driven by the increase in net sales, partially offset by increased legal fees for litigation activity and higher salary and related expenses resulting from the executive management changes and recently announced new hires. Our cash balance at September 30, 2019, was $5.1 million, which included $0.5 million for the exercise of outstanding warrants.

RESULTS OF OPERATIONS

Three months ended September 30, 2019 compared to September 30, 2018

Net Sales

The following table summarizes our net sales for the three months ended September 30, 2019 and 2018:


	Three Months Ended September 30,				Change from Prior Year					% of Sales
	2019		2018		$			%		2019	2018
Sales
Domestic	$	5,856,203	$	3,699,410	$	2,156,793		58.3%		88.5%	81.4%
International		761,194		847,777		(86,583	)	(10.2%	)	11.5%	18.6%
Total	$	6,617,397	$	4,547,187	$	2,070,210		45.5%

Total net sales increased $2.1 million or 45.5% for the three months ended September 30, 2019, compared with the same period last year. This growth was driven by organic growth mostly from increased volume and to a lesser extent from price increases, two unusually large orders, one from a domestic distributor and one from a new customer in Europe, as well as clinical trials. We cannot predict whether such large orders will continue in the future. We ended the quarter with open orders totaling $0.8 million.

- 16 -

Excluding the two large orders, clinical trials in both periods, and adjusting for the open orders, net sales increased in excess of 25% year over year. We believe organic volume growth continues to be due to growth in the diagnosis of PIDD and expansion into the neurology market with the expanded Hizentra® indication for CIDP. Internationally, net sales were down mostly due to open orders totaling $0.1 million at the end of the period.

Gross Profit

Our gross profit for the three months ended September 30, 2019 and 2018 is as follows:


	Three Months Ended September 30,				Change from Prior Year
	2019		2018		$		%
Gross Profit	$	4,382,908	$	2,891,568	$	1,491,340	51.6%
Stated as a Percentage of Net Sales		66.2%		63.6%

Gross profit increased $1.5 million or 51.6% in the three months ended September 30, 2019, compared to the same period in 2018. This increase in the quarter was mostly driven by the increase in net sales. Gross profit improved 2.6 percentage points compared with the same period last year, mostly due to price increases.

Selling, general and administrative, Litigation and Research and development

Our selling, general and administrative expenses, litigation, and research and development costs for the three months ended September 30, 2019 and 2018 are as follows:


	Three Months Ended September 30,				Change from Prior Year
	2019		2018		$		%
Selling, general and administrative	$	2,441,381		1,917,127	$	524,254	27.3%
Litigation		864,009		286,487		577,522	201.6%
Research and development		170,260		126,923		43,337	34.1%
	$	3,475,650		2,330,537	$	1,145,113	49.1%
Stated as a Percentage of Net Sales		52.5%		51.3%

Selling, general and administrative expenses during the three months ended September 30, 2019 increased $0.5 million, or 27.4%, over the same period last year. Driving the increase was higher salary and related benefits including $0.3 million of stock option expense, due to the addition of the Executive Chairman of the Board, our new President and Chief Executive Officer and other executive changes, including the additions of Vice Presidents of Medical Affairs, Growth and Innovation, and Sales and Marketing, adding $0.6 million year over year. Partially offsetting these increases was attrition in regulatory totaling $0.1 million.

Litigation fees continue to be higher than the previous year period, up $0.6 million as we continue to defend ourselves against our competitor through several motions and court proceedings, as well as in the patent office. We have had some favorable rulings in the courts and have filed motions for court costs and attorney fees. Refer to Note 4 Legal Proceedings in the Notes to the Financial Statements.

Research and development expenses increased $43,337, or 34.1%, over last year due to increased headcount and expanded product development initiatives compared to last year.

Depreciation and amortization

Depreciation and amortization expense increased by 5.7% to $82,774 in the three months ended September 30, 2019 compared with $78,345 in the three months ended September 30, 2018. We continued to invest in capital assets, mostly related to production equipment, computer equipment and leasehold improvements, and in patent applications and their maintenance.

Net Income


	Three Months Ended September 30,				Change from Prior Year
	2019		2018		$		%
Net Income	$	651,813	$	386,553	$	265,260	68.6%
Stated as a Percentage of Net Sales		9.9%		8.5%

- 17 -

Our net income for the three months ended September 30, 2019 was $0.7 million compared to $0.4 million for the same period last year. The increase is mostly driven by the increase in net sales, partially offset by selling general and administrative fees, as well as litigation fees as described above.

Nine months ended September 30, 2019 compared to September 30, 2018

Net Sales

The following table summarizes our net sales for the nine months ended September 30, 2019 and 2018:


	Nine months Ended September 30,				Change from Prior Year			% of Sales
	2019		2018		$		%	2019	2018
Sales
Domestic	$	14,308,994	$	10,657,010	$	3,651,984	34.3%	84.5%	81.5%
International		2,631,493		2,425,727		205,766	8.5%	15.5%	18.5%
Total	$	16,940,487	$	13,082,737	$	3,857,750	29.5%

Total net sales increased $3.9 million or 29.5% for the nine months ended September 30, 2019 driven by growth in all product categories (pumps, needles, and tubing) in the Freedom Infusion System. The nine month period includes clinical trials at several customers, and two unusually large orders from a domestic distributor and a new customer in Europe. We ended the third quarter with $0.8 million in open orders. Excluding both large orders, clinical trials and adding in the open orders, the net sales increase would have been 24%, demonstrating strength in continued organic growth driven by increased volume and to a lesser extent price increases. We believe the organic volume growth continues to be driven by growth in the diagnosis of PIDD and expansion into the neurology market with expanded Hizentra® indication for CIDP.

Gross Profit

Our gross profit for the nine months ended September 30, 2019 and 2018 is as follows:


	Nine months Ended September 30,				Change from Prior Year
	2019		2018		$		%
Gross Profit	$	10,906,526	$	8,096,976	$	2,809,550	34.7%
Stated as a Percentage of Net Sales		64.4%		61.9%

Gross profit increased $2.8 million or 34.7% in the nine months ended September 30, 2019, compared to the same period last year. Gross margin improved 2.5 percentage points during the period and was driven mostly by price increases and to a lesser extent some production efficiencies.

Selling, general and administrative, Litigation and Research and development

Our selling, general and administrative expenses, litigation and research and development costs for the nine months ended September 30, 2019 and 2018 are as follows:


	Nine months Ended September 30,				Change from Prior Year
	2019		2018		$		%
Selling, general and administrative	$	6,976,684	$	5,513,727	$	1,462,957	26.5%
Litigation		2,481,471		592,787		1,888,684	318.6%
Research and development		450,454		160,735		289,719	180.3%
	$	9,908,609	$	6,267,249	$	3,641,360	58.1%
Stated as a Percentage of Net Sales		58.5%		47.9%

Selling, general and administrative expenses increased $1.5 million, or 26.5%, during the nine months ended September 30, 2019 compared to the same period last year. The increase is mostly driven by higher salary and related benefits totaling $1.3 million, due to the addition of the Executive Chairman of the Board, our new President and Chief Executive Officer, including a performance bonus payment to our former interim Chief Executive Officer in the amount of $0.3 million, as well as the addition of Vice Presidents for

- 18 -

Medical Affairs, Growth and Innovation and Sales and Marketing and other executed changes. Included in the $1.3 million of salary and related benefits is $0.5 million in stock option expense. Higher consulting fees of $0.2 million related to strategic initiatives, and higher investor relation expenses and director fees also contributed $0.2 million to the increase. Partially offsetting these increases was lower recruiting fees of $0.2 million.

Litigation expenses continued to increase, up $1.9 million compared to the same period last year as we continue to defend ourselves against our competitor through several motions and court proceedings, as well as in the patent office. We have had several favorable rulings in the courts and have filed motions for court costs and attorney fees. Refer to Note 4 Legal Proceedings in the Notes to the Financial Statements.

Research and development expense increased by $0.3 million, or 180.3%, primarily due to increased headcount and expanded product development initiatives compared to last year.

Depreciation and amortization

Depreciation and amortization expense increased by 10.4% to $252,594 in the nine months ended September 30, 2019 compared with $228,900 in the nine months ended September 30, 2018. We continued to invest in capital assets, mostly related to production equipment, computer equipment and leasehold improvements, and in patent applications and their maintenance.

Net Income


	Nine months Ended September 30,				Change from Prior Year
	2019		2018		$			%
Net Income	$	644,606	$	1,265,703	$	(621,097	)	(49.1%)
Stated as a Percentage of Net Sales		3.8%		9.7%

Our net income for the nine months ended September 30, 2019 was $0.6 million compared to a net income of $1.3 million for the nine months ended September 30, 2018. This decrease was driven by increased selling, general and administrative expenses and litigation fees, as described above.

LIQUIDITY AND CAPITAL RESOURCES

Our principal source of liquidity is our cash of $5.1 million as of September 30, 2019. Additionally, we have a $1.5 million line of credit with no outstanding amounts against it. Our principal source of operating cash inflows is from sales of our products to customers. Our principal cash outflows relate to the purchase and production of inventory and related costs, selling, general and administrative expenses and professional fees.

We believe that as of September 30, 2019, cash on hand and cash expected to be generated from future operating activities will be sufficient to fund our operations, including further research and development and capital expenditures, for the next 12 months. We believe KORU Medical’s home infusion products continue to find a solid following in the subcutaneous immunoglobulin (“SCIg”) market and into new markets like neurology where Hizentra® received an expanded indication for CIDP.

We continue to be in litigation with a competitor, EMED Technologies Corp. (“EMED”) and have incurred a significant amount of legal fees in connection with that process. Although the Company believes it has meritorious claims and defenses in the actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Cash Flows

The following table summarizes our cash flows:


	Nine months Ended September 30, 2019			Nine months Ended September 30, 2018
Net cash (used in)/provided by operating activities	$	(502,014	)	$	1,352,899
Net cash provided by/(used in) investing activities	$	1,389,281		$	(1,727,598	)
Net cash provided by financing activities	$	502,958		$	49,495

- 19 -

Operating Activities

Net cash used in operating activities of $0.5 million for the nine months ended September 30, 2019 was mostly attributable to increased accounts receivable of $2.1 million as one of our major customer’s payment terms changed on January 1, 2019 from net 30 to net 60 days, increased inventory of $0.6 million as we build stock to keep pace with sales growth, as well as severance payments and payments for insurance renewals. Partially offsetting these were our non-cash charges for stock based compensation of $0.9 million and depreciation and amortization of long lived tangible and intangible asset of $0.3 million, as well as increases in accounts payable of $0.4 million primarily for major supplier invoices and accrued expenses of $0.5 million primarily due to legal fees and bonus accruals.

Net cash provided by operating activities of $1.4 million for the nine months ended September 30, 2018 was primarily the result of net income of $1.3 million, non-cash charges of $0.2 million for depreciation and amortization of long lived tangible and intangible assets and stock based compensation of $0.2 million, a decrease in accounts receivable of $0.4 million and an increase in accounts payable of $0.1 million. Partially offsetting these were increases in inventory and payments for insurance renewals and severance, bonus and commission payments accrued for at December 31, 2017.

Investing Activities

Our net cash provided by investing activities of $1.4 million for the nine months ended September 30, 2019 was mostly the result of the maturation of a certificate of deposit for $1.5 million and the sale of the house the Company owned for $0.2 million, offset by capital expenditures of $0.2 million and patent applications and maintenance of existing applications of $0.2 million. Our net cash used for investing activities of $1.7 million for the nine months ended September 30, 2018 was mostly the result of the purchase of a certificate of deposit.

Financing Activities

The $0.5 million provided by financing activities for the nine months ended September 30, 2019 is a result of warrants and options exercised during the period. Net cash provided by financing activities was $49,495 for the nine months ended September 30, 2018 mostly resulted from the exercise of options.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

- 20 -

NON-GAAP FINANCIAL MEASURES

Management of the Company believes that investors’ understanding of the Company’s performance is enhanced by disclosing non-GAAP financial measures as a reasonable basis for comparison of the Company’s ongoing results of operations. These non-GAAP measures should not be considered a substitute for GAAP-basis measures and results. Our non-GAAP measures may not be comparable to non-GAAP measures of other companies. The table below provides a disclosure of these non-GAAP financial measures to the most closely analogous measure determined in accordance with GAAP.

Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

We disclose and discuss Adjusted EBITDA as a non-GAAP financial measure in our public releases, including quarterly earnings releases, and other filings with the Securities and Exchange Commission. We define Adjusted EBITDA as earnings (net income) before interest, income taxes, depreciation and amortization, reorganization charges, litigation and stock option expenses. We believe that Adjusted EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of Adjusted EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. Adjusted EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations. Because management uses Adjusted EBITDA for such purposes, the Company uses Adjusted EBITDA as a significant criterion for determining the amount of annual cash incentive compensation paid to our executive officers and employees. We have historically found that Adjusted EBITDA is superior to other metrics for our company-wide cash incentive program, as it is more easily explained and understood by our typical employee.

A reconciliation of our non-GAAP measures is below:


	Three Months Ended						Nine Months Ended
Reconciliation of GAAP Net Income	September 30,						September 30,
to Non-GAAP Adjusted EBITDA:	2019			2018			2019			2018
GAAP Net Income	$	651,813		$	386,553		$	644,606		$	1,265,703
Tax Expense		186,681			103,263			189,265			337,956
Depreciation/Amortization		82,774			78,345			252,594			228,900
Interest Income, Net		(23,368	)		(6,972	)		(59,091	)		(13,088	)
Reorganization Charges		—			232,471			354,926			383,668
Litigation		864,009			286,487			2,481,471			592,787
Stock Option Expense		324,135			24,922			640,775			51,592
Non-GAAP Adjusted EBITDA	$	2,086,044		$	1,105,069		$	4,504,546		$	2,847,518

Reorganization Charges. We have excluded the effect of Reorganization Charges in calculating our non-GAAP Adjusted EBITDA measure. We incurred significant expenses in connection with the termination and replacement of C-suite executives and senior management which we would not otherwise incur in periods presented as part of our continuing operations. Reorganization charges include costs related to the replacement of C-suite executives including a transition bonus and recruiting fees, prior to March 31, 2019.

- 21 -

Litigation. We have excluded litigation expenses in calculating our non-GAAP Adjusted EBITDA measure. We continue to evaluate our business performance excluding litigation fees, which we expect to continue in future periods.

Stock Option Expense. We have excluded the effect of stock option expenses in calculating our non-GAAP Adjusted EBITDA measure. Although stock option compensation is a key incentive offered to our employees, we continue to evaluate our business performance excluding stock option compensation expenses. We record non-cash compensation expense related to grants of options and depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.

PART I – ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

PART I – ITEM 4. CONTROLS AND PROCEDURES

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2019, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

- 22 -

- 23 -

ITEM 1A. RISK FACTORS

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. The following are material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2018:

Our common stock is now listed on the Nasdaq Stock Market LLC (Nasdaq Capital Market) and is no longer subject to penny stock regulations.

If we fail to continue to meet the listing standards of the Nasdaq Stock Market LLC (“Nasdaq”), our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.

Our common stock is currently listed on the Nasdaq Capital Market. Nasdaq has requirements that a company must meet in order to remain listed on Nasdaq. In particular, Nasdaq rules require us to maintain a minimum bid price of $1.00 per share of our common stock. If the closing bid price of our common stock were to fall below $1.00 per share for 30 consecutive trading days or we do not meet other listing requirements, we would fail to be in compliance with Nasdaq listing standards. There can be no assurance that we will continue to meet the minimum bid price requirement, or any other requirement in the future. If we fail to meet the minimum bid price requirement, The Nasdaq Stock Market LLC may initiate the delisting process. In addition, we may be unable to meet other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholders’ equity or market values of our common stock in which case, our common stock could be delisted. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.

PART II – ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On February 20, 2019, the Board of Directors of the Company approved non-employee director compensation of $50,000 annually effective January 1, 2019, and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock at the end of each fiscal quarter. The Company issued an aggregate of 12,447 and 47,143 shares of common stock to its non-employee directors during the three and nine month period ended September 30, 2019, respectively.

Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000, half in cash and half in common stock, to be paid on April 1, 2019. The number of shares of common stock issued was 90,604 based upon the closing price of the Common Stock of the Company on February 1, 2019 as reported by the OTCQX.

During the three months ended September 30, 2019, 350,000 options were issued to key employees under the Company’s 2015 Stock Option Plan, as amended (the “Plan”). There are 6,000,000 options authorized for issuance under the Plan. During the three months ended September 30, 2019, 95,000 options were exercised at an exercise price of $0.36.

The following table describes the options issued to Company key employees for the three months ended September 30, 2019:


Date Issued	Options Awarded	Vesting Schedule	Exercise Price $
7/1/2019	250,000	Vest 25% annually on anniversary date	2.83
8/19/2019	100,000	Vest 25% annually on anniversary date	3.15

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

- 24 -

PART II – ITEM 6. EXHIBITS.


31.1	Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

101*	Interactive Data Files of Financial Statements and Notes.

* In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.

- 25 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPRO MED SYSTEMS, INC.

November 6, 2019	/s/ Donald B. Pettigrew
	Donald B. Pettigrew, President and Chief Executive Officer (Principal Executive Officer)

November 6, 2019	/s/ Karen Fisher
	Karen Fisher, Chief Financial Officer and Treasurer (Principal Financial Officer)

- 26 -

EX-31 2 ex_31-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

I, Donald B. Pettigrew, Principal Executive Officer, certify that:


1)	I have reviewed this Quarterly Report on Form 10-Q of Repro Med Systems, Inc. (the “Report”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2019

/s/ Donald B. Pettigrew

Donald B. Pettigrew

President and Chief Executive Officer

EX-31 3 ex_31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 31.2

RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

I, Karen Fisher, Principal Financial Officer, certify that:


1)	I have reviewed this Quarterly Report on Form 10-Q of Repro Med Systems, Inc. (the “Report”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2019

/s/ Karen Fisher

Karen Fisher

Chief Financial Officer and Treasurer

EX-32 4 ex_32-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro Med Systems, Inc. (the “Company”) on Form 10-Q (the “Report”) for the quarterly period ending September 30, 2019 as filed with the Securities and Exchange Commission, I, Donald B. Pettigrew, Principal Executive Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 6, 2019

/s/ Donald B. Pettigrew

Donald B. Pettigrew

President and Chief Executive Officer

EX-32 5 ex_32-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro Med Systems, Inc. (the “Company”) on Form 10-Q (the “Report”) for the quarterly period ending September 30, 2019 as filed with the Securities and Exchange Commission, I, Karen Fisher, Principal Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 6, 2019

/s/ Karen Fisher

Karen Fisher

Chief Financial Officer and Treasurer

EX-101.INS 6 krmd-20190930.xml XBRL INSTANCE FILE 0000704440 2019-01-01 2019-09-30 0000704440 2019-09-30 0000704440 2018-12-31 0000704440 2017-12-31 0000704440 2018-09-30 0000704440 2018-01-01 2018-09-30 0000704440 2019-07-01 2019-09-30 0000704440 2018-07-01 2018-09-30 0000704440 us-gaap:CertificatesOfDepositMember 2019-09-30 0000704440 us-gaap:MoneyMarketFundsMember 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2019-01-01 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember srt:PresidentMember 2019-01-01 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember srt:PresidentMember 2018-01-01 2018-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember srt:PresidentMember 2019-07-01 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember srt:PresidentMember 2018-07-01 2018-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2018-01-01 2018-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2019-07-01 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2018-07-01 2018-09-30 0000704440 us-gaap:LandMember 2019-09-30 0000704440 us-gaap:LandMember 2018-12-31 0000704440 us-gaap:BuildingMember 2019-09-30 0000704440 us-gaap:BuildingMember 2018-12-31 0000704440 krmd:FurnitureOfficeEquipmentAndLeaseHoldImprovementsMember 2019-09-30 0000704440 krmd:FurnitureOfficeEquipmentAndLeaseHoldImprovementsMember 2018-12-31 0000704440 krmd:ManufacturingEquipmentAndToolingMember 2019-09-30 0000704440 krmd:ManufacturingEquipmentAndToolingMember 2018-12-31 0000704440 2019-05-20 2019-05-21 0000704440 krmd:EMEDTechnologiesCorporationMember 2019-04-01 2019-04-30 0000704440 krmd:EMEDTechnologiesCorporationMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2018-01-01 2018-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2018-01-01 2018-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember srt:MinimumMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember srt:MaximumMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2018-12-31 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2017-12-31 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember 2018-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2018-12-31 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2019-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2017-12-31 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember 2018-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:KeyEmployeesMember 2019-01-01 2019-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:ExercisePrice1Member krmd:TimeBasedSharesOptionsMember 2019-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember krmd:ExercisePrice2Member 2019-09-30 0000704440 krmd:StockOptionPlan2015Member us-gaap:PerformanceSharesMember krmd:ExercisePrice2Member 2019-01-01 2019-09-30 0000704440 krmd:ChiefExecutiveOfficerMrGoldbergerMember krmd:EmploymentAgreementMember 2019-02-01 2019-02-02 0000704440 krmd:IndependentDirectorsMember 2019-02-19 2019-02-20 0000704440 krmd:ChiefExecutiveOfficerMrGoldbergerMember krmd:EmploymentAgreementMember 2019-03-27 2019-04-02 0000704440 krmd:IndependentDirectorsMember 2019-01-01 2019-01-02 0000704440 krmd:KeyBankNationalAssociationMember us-gaap:LineOfCreditMember 2018-02-08 0000704440 2018-02-07 2018-02-08 0000704440 srt:MinimumMember 2019-09-30 0000704440 srt:MaximumMember 2019-09-30 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2019-02-28 0000704440 krmd:LeaseAgreementMember us-gaap:BuildingMember krmd:Director1Member 2019-03-01 0000704440 2019-11-06 0000704440 krmd:EMEDTechnologiesCorporationMember 2019-08-29 2019-08-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember srt:MinimumMember 2018-01-01 2018-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:TimeBasedSharesOptionsMember srt:MaximumMember 2018-01-01 2018-09-30 0000704440 krmd:StockOptionPlan2015Member krmd:ExercisePrice1Member krmd:TimeBasedSharesOptionsMember 2019-01-01 2019-09-30 0000704440 srt:BoardOfDirectorsChairmanMember 2019-01-01 2019-09-30 0000704440 us-gaap:MoneyMarketFundsMember 2019-09-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares krmd:Number xbrli:pure REPRO MED SYSTEMS INC 0000704440 10-Q 2019-09-30 false --12-31 Yes Non-accelerated Filer true false false Q3 2019 0-12305 NY Yes

5129028

3738803

3974536

3649332

103465

378000

1517927

3546634

1425854

2738682

2103879

453151

246591

11867495

9033054

636928

858781

786164

632156

1466

19582

13717123

10545039

3763

874977

453498

1178702

688649

111359

421714

16608

2303555

1584232

133097

2708331

1584232

422286

409329

5985636

4595214

4945074

4300468

11352996 9305011

344204

11008792

8960807

13717123

10545039

38734083

38875737

39298408

38985684

38534021

38104393

39022298

38194682

0.02

0.03

0.02

0.01

0.02

0.03

0.02

0.01

644606

1265703

651813

386553

189265

337956

186681

103263

833871

1603659

838494

489816

88548

2832

14010

7130

59091

13088

23368

6972

49740

6000

-20283

-16256

-9358

-5842

745323

1600827

824484

482686

10161203

6496149

3558424

2408882

252594

228900

82774

78345

450454

160735

170260

126923

6976684

5513727

2441381

1917127

10906526

8096976

4382908

2891568

6033961

4985761

2234489

1655619

16940487

13082737

6617397

4547187

1500000

158193

188006

-502014

1352899

-16608

-60852

490053

-30823

-310355

-213700

421479

137521

206560

177346

634803

290722

2120780

-351319

134563

10834

3763

16860

897300

154925

188274

137858

1389281

-1727598

2820 1755

502958

49495

1390225

-325204

280

256525

103333

NOTE 2  RELATED PARTY TRANSACTIONS   LEASED AIRCRAFT   From 1992 to 2018, we leased an aircraft from AMI Aviation, Inc., of which our former President and Chief Executive Officer, Andrew Sealfon, was a majority shareholder. The lease payments were zero and $1,292 for the three months ended September 30, 2019 and 2018, respectively and zero and $9,045 for the nine months ended September 30, 2019 and 2018 respectively. Upon the termination of Mr. Sealfon as President and Chief Executive Officer on July 25, 2018, the Company ceased leasing this aircraft.   BUILDING LEASE   Mr. Pastreich, a former director, is a principal in the entity that owns the building leased by us for our corporate headquarters and manufacturing facility at 24 Carpenter Road, Chester, New York 10918.  On February 28, 2019, we completed year twenty of a twenty year lease with monthly lease payments of $11,042.  On November 14, 2017, we executed a lease extension, which calls for six month extensions beginning March 1, 2019 with the option to renew six times at a monthly lease amount of $12,088. The Company exercised three additional renewal options commencing September 1, 2019 through February 28, 2021.   The lease payments were $36,264 and $33,126 for the three months ended September 30, 2019 and 2018, respectively, and $106,700 and $99,378 for the nine months ended September 30, 2019 and 2018, respectively. The Company also paid property taxes in the amount of $13,749 and $12,431 for the three months ended September 30, 2019 and 2018, respectively and $39,165 and $37,863 for the nine months ended September 30, 2019 and 2018, respectively.

NOTE 3 PROPERTY AND EQUIPMENT   Property and equipment consists of the following at: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="335"> </td> <td width="9"> </td> <td width="9"> </td> <td width="115"> </td> <td width="19"> </td> <td width="9"> </td> <td width="115"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="335">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1.33px solid #000000;" colspan="2" valign="bottom" width="125"> September 30, 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1.33px solid #000000;" colspan="2" valign="bottom" width="125"> December 31, 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="335">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="115">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="115">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="335"> Land </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> — </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> 54,030 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="335"> Building </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="115"> — </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="115"> 171,094 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="335"> Furniture, office equipment, and leasehold improvements </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> 1,120,416 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> 1,058,507 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="335"> Manufacturing equipment and tooling </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="115"> 1,309,172 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="115"> 1,279,865 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="335">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> 2,429,588 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="115"> 2,563,496 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="335"> Less: accumulated depreciation </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="115"> (1,792,660 </td> <td style="margin-top: 0px;" valign="bottom" width="19"> ) </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="115"> (1,704,715 </td> <td style="margin-top: 0px;" valign="bottom" width="9"> ) </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="335"> Property and equipment, net </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #d9d9d9;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #d9d9d9;" valign="bottom" width="115"> 636,928 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #d9d9d9;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #d9d9d9;" valign="bottom" width="115"> 858,781 </td> <td style="margin-top: 0px; background-color: #d9d9d9;" valign="bottom" width="9">   </td> </tr> </table>   On May 21, 2019, the Company sold the house it owned for $0.2 million.   Depreciation expense was $69,740 and $68,991 for the three months ended September 30, 2019 and 2018, respectively, and $218,328 and $202,975 for the nine months ended September 30, 2019 and 2018, respectively.

NOTE 5  STOCK-BASED COMPENSATION   On June 29, 2016, the Board of Directors amended the 2015 Stock Option Plan (as amended, the “Plan”)  authorizing the Company to grant awards to certain executives, key employees, and consultants under the Plan, which was approved by shareholders at the Annual Meeting held on September 6, 2016.  The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed 6,000,000 pursuant to an amendment to the Plan approved by shareholders on April 23, 2019 at the 2019 Annual Meeting of Shareholders.   As of September 30, 2019, the Company had 3,897,000 time based stock options outstanding to certain executives, key employees and consultants under the Plan, of which 1,650,000 were issued during the nine months ended September 30, 2019.  The Company also had 1,000,000 performance based options outstanding under the Plan as of September 30, 2019, to its President and Chief Executive Officer, of which all were issued during the nine months ending September 30, 2019.   On February 20, 2019, the Board of Directors of the Company approved an increase in compensation for each non-employee director from $25,000 to $50,000 annually effective January 1, 2019 and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock at the end of each fiscal quarter.   Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000 to be paid half in cash and half in stock on April 1, 2019.  The number of shares that were issued totaled 90,604 and was based upon the closing price of the Common Stock of the Company on February 1, 2019 as reported by the OTCQX.  These shares were issued on April 3, 2019.   2015 STOCK OPTION PLAN, as amended   Time Based Stock Options   The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and September 30, 2018 was $1.33 and $0.68, respectively.  The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options.  The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.   <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="201"> </td> <td width="9"> </td> <td width="9"> </td> <td width="86"> </td> <td width="19"> </td> <td width="9"> </td> <td width="86"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px;" width="201">   </td> <td style="margin-top: 0px;" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" width="211"> September 30, </td> <td style="margin-top: 0px;" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="96"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Dividend yield </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected Volatility </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 56.1 – 60.7% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 62.8 – 65.2% </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Weighted-average volatility </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected dividends </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Expected term (in years) </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 5 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Risk-free rate </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 1.60 – 2.72% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 2.80 – 2.90% </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> </table>   The following table summarizes the status of the Plan with respect to time based stock options: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="301"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="10" valign="bottom" width="399"> Nine months Ended September 30, </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="4" valign="bottom" width="179"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" valign="bottom" width="189"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="69"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="78"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="78">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at January 1 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 2,419,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.00 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,038,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Granted </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,650,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.92 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,018,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.23 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Exercised </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 160,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.37 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 125,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Forfeited </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 12,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.87 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 12,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.87 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at September 30 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 3,897,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,919,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.85 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Options exercisable at September 30 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,037,885 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.81 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 666,969 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.40 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="301"> Weighted average fair value of options granted during the period </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 1.33 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 0.68 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Stock-based compensation expense </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 473,139 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 51,592 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> </table>   Total stock-based compensation expense totaled $473,139 and $51,592 for the nine months ended September 30, 2019 and 2018, respectively. Cash received from option exercises for the nine months ended September 30, 2019 and 2018 was $58,900 and $51,250, respectively.   The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and 2018, was $1.33 and $0.68, respectively.  The total intrinsic value of options exercised during the nine months ended September 30, 2019 and 2018, was $30,022 and $30,664, respectively.   The following table presents information pertaining to options outstanding at September 30, 2019: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="174"> </td> <td width="11"> </td> <td width="86"> </td> <td width="19"> </td> <td width="86"> </td> <td width="18"> </td> <td width="10"> </td> <td width="84"> </td> <td width="18"> </td> <td width="86"> </td> <td width="19"> </td> <td width="11"> </td> <td width="84"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="174"> Range of Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Outstanding </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Weighted Average Remaining Contractual Life </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="94"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Exercisable </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="174">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="174"> $ 0.38 – 3.15 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 3,897,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 7 years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 1.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 1,037,885 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 0.81 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> </table>   As of September 30, 2019, there was $2,802,411 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 42 months. The total fair value of shares vested as of September 30, 2019 and 2018, was $506,729 and $139,569, respectively.   Performance Based Stock Options   The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and 2018 was $1.16 and zero, respectively.  The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018.  Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options.  The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="201"> </td> <td width="9"> </td> <td width="9"> </td> <td width="86"> </td> <td width="19"> </td> <td width="9"> </td> <td width="86"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px;" width="201">   </td> <td style="margin-top: 0px;" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" width="211"> September 30, </td> <td style="margin-top: 0px;" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="96"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Dividend yield </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected Volatility </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 58.9% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Weighted-average volatility </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected dividends </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Expected term (in years) </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Risk-free rate </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 2.07% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> </table>   The following table summarizes the status of the Plan with respect to performance based stock options: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="301"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="10" valign="bottom" width="399"> Nine months Ended September 30, </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="4" valign="bottom" width="179"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" valign="bottom" width="189"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="69"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="78"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="78">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at January 1 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Granted </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,000,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.70 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Exercised </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Forfeited </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at September 30 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,000,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Options exercisable at September 30 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="301"> Weighted average fair value of options granted during the period </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 1.16 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Stock-based compensation expense </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 167,636 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> </table>   Total performance stock-based compensation expense totaled $167,636 and zero for the nine months ended September 30, 2019 and 2018, respectively.   The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and September 30, 2018, was $1.16 and zero, respectively.   The following table presents information pertaining to performance based options outstanding at September 30, 2019: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="174"> </td> <td width="11"> </td> <td width="86"> </td> <td width="19"> </td> <td width="86"> </td> <td width="18"> </td> <td width="10"> </td> <td width="84"> </td> <td width="18"> </td> <td width="86"> </td> <td width="19"> </td> <td width="11"> </td> <td width="84"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="174"> Range of Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Outstanding </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Weighted Average Remaining Contractual Life </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="94"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Exercisable </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="174">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="174"> $1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 1,000,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> </table>   As of September 30, 2019, there was $994,925 of total unrecognized compensation cost related to non-vested performance share option based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 31 months. The total fair value of shares vested as of September 30, 2019 and 2018 was zero for both periods.

NOTE 6  DEBT OBLIGATIONS   On February 8, 2018, the Company issued a Promissory Note to KeyBank National Association (“KeyBank”) in the amount of $1.5 million as a variable rate revolving line of credit loan due on demand with an interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million.  The Company entered into this arrangement to establish a credit lending history and, in the event needed, to have additional cash on hand for future expansion.  On September 25, 2018, KeyBank released the certificate of deposit as collateral for the loan and the Company executed a Commercial Security Agreement as collateral for the loan. As of September 30, 2019, the Company had no outstanding amounts against the line of credit.

NOTE 7  LEASES   We have finance and operating leases for our corporate office and certain office and computer equipment.  Our leases have remaining lease terms of 1 to 3 years, some of which include options to extend the leases annually and some with options to terminate the leases within 1 year.   The components of lease expense were as follows: <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 245px"> </td> <td style="width: 10px"> </td> <td style="width: 9px"> </td> <td style="width: 124px"> </td> <td style="width: 19px"> </td> <td style="width: 10px"> </td> <td style="width: 123px"> </td> <td style="width: 10px"> </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 245px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; vertical-align: top; width: 133px"> Three Months Ended September 30, 2019 </td> <td style="margin-top: 0px; vertical-align: top; width: 19px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; vertical-align: bottom; width: 133px"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 245px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 124px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 123px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 245px"> Operating lease cost </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 124px"> 37,922 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 10px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 123px"> 111,672 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 245px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 124px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 123px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 245px"> Finance lease cost: </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 124px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 123px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 245px"> Amortization of right-of-use assets </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 124px"> 1,061 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 123px"> 3,182 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 245px"> Interest on lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 124px"> 47 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 123px"> 178 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 10px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 245px"> Total finance lease cost </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> <td style="margin-top: 0px; border-top: #000000 1px solid; border-bottom: #000000 3px double; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-top: #000000 1px solid; border-bottom: #000000 3px double; vertical-align: bottom; width: 124px"> 1,108 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; vertical-align: bottom; width: 10px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; vertical-align: bottom; width: 123px"> 3,360 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 10px">   </td> </tr> </table>   Supplemental cash flow information related to leases was as follows: <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 429px"> </td> <td style="width: 9px"> </td> <td style="width: 121px"> </td> <td style="width: 19px"> </td> <td style="width: 9px"> </td> <td style="width: 121px"> </td> <td style="width: 9px"> </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 429px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; vertical-align: bottom; width: 130px"> Three Months Ended September 30, 2019 </td> <td style="margin-top: 0px; vertical-align: top; width: 19px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; vertical-align: bottom; width: 130px"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 429px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 429px"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 429px"> Finance cash flows from finance leases </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px"> 1,053 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px"> 3,122 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 429px"> Finance lease cost: </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 121px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 429px"> Amortization of right-of-use assets </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px"> 1,061 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; vertical-align: bottom; width: 121px"> 3,182 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 429px"> Interest on lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 121px"> 47 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; vertical-align: bottom; width: 121px"> 178 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 429px"> Total finance lease cost </td> <td style="margin-top: 0px; border-top: #000000 1px solid; border-bottom: #000000 3px double; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-top: #000000 1px solid; border-bottom: #000000 3px double; vertical-align: bottom; width: 121px"> 1,108 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; vertical-align: bottom; width: 121px"> 3,360 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> </table>   Supplemental balance sheet information related to leases was as follows: <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 262.22px"> </td> <td style="width: 8.88px"> </td> <td style="width: 8.88px"> </td> <td style="width: 120.88px"> </td> <td style="width: 10.66px"> </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: top">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; width: 129.77px; vertical-align: bottom"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom"> Operating Leases </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 120.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Operating lease right-of-use assets </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 120.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Operating lease current liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 135,275 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom"> Operating lease long term liabilities </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 120.88px; vertical-align: bottom"> 271,679 </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Total operating lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 120.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom"> Finance Leases </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 120.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Property and equipment, at cost </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 6,363 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom"> Accumulated depreciation </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 120.88px; vertical-align: bottom"> 3,182 </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Property and equipment, net </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 3,181 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 120.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Finance lease current liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 3,242 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; width: 262.22px; vertical-align: bottom"> Finance lease long term liabilities </td> <td style="margin-top: 0px; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; width: 120.88px; vertical-align: bottom"> — </td> <td style="margin-top: 0px; width: 10.66px; vertical-align: bottom">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; width: 262.22px; vertical-align: bottom"> Total finance lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; width: 8.88px; vertical-align: bottom"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; width: 120.88px; vertical-align: bottom"> 3,242 </td> <td style="margin-top: 0px; background-color: #e6e6e6; width: 10.66px; vertical-align: bottom">   </td> </tr> </table>   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 268px"> </td> <td style="width: 9px"> </td> <td style="width: 120px"> </td> <td style="width: 9px"> </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 268px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; vertical-align: bottom; width: 120px"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 268px"> Weighted Average Remaining Lease Term </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 120px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 268px"> Operating leases </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 120px"> 3 Years </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 268px"> Finance leases </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 120px"> 1 Year </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 268px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 120px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 268px"> Weighted Average Discount Rate </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 120px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; vertical-align: bottom; width: 268px"> Operating leases </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; vertical-align: bottom; width: 120px"> 4.75% </td> <td style="margin-top: 0px; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 268px"> Finance leases </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 120px"> 4.75% </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> </table>   Maturities of lease liabilities are as follows:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 187px"> </td> <td style="width: 9px"> </td> <td style="width: 9px"> </td> <td style="width: 105px"> </td> <td style="width: 19px"> </td> <td style="width: 9px"> </td> <td style="width: 105px"> </td> <td style="width: 9px"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 187px"> Year Ending December 31, </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: top; width: 9px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> Operating Leases </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> Finance Leases </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 187px"> 2019 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 37,922 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 1,100 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 187px"> 2020 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 105px"> 151,685 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 105px"> 2,206 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 187px"> 2021 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 149,476 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 187px"> 2022 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 105px"> 97,256 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 105px"> — </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 187px"> Total lease payments </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 436,339 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 3,306 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 187px"> Less imputed interest </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 105px"> (29,385 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px"> ) </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 105px"> (64 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px"> ) </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 187px"> Total </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: top; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #e6e6e6; vertical-align: bottom; width: 105px"> 3,242 </td> <td style="margin-top: 0px; background-color: #e6e6e6; vertical-align: bottom; width: 9px">   </td> </tr> </table>

NATURE OF OPERATIONS   REPRO MED SYSTEMS, INC. (the “Company”, “KORU Medical” or “we”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management.  The Company operates as one segment.

FISCAL YEAR END   The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION   The accompanying unaudited financial statements as of September 30, 2019, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.   In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of September 30, 2019, and the results of operations and cash flow for the three and nine month periods ended September 30, 2019, and 2018.   The results of operations for the nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for the full year.  These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the twelve months ended December 31, 2018, as filed with the Securities and Exchange Commission on Form 10-K.

CASH AND CASH EQUIVALENTS   For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents.   The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.

CERTIFICATES OF DEPOSIT   The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019, at which time the funds were moved into a money market account earning interest at 2.25%.  Effective September 24, 2019, the money market account interest rate dropped to 1.85%.

INVENTORY   Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.

PATENTS   Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.

INCOME TAXES   Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences.   The Company believes that it has no uncertain tax positions requiring disclosure or adjustment.  Generally, tax years starting with 2016 are subject to examination by income tax authorities.

PROPERTY, EQUIPMENT, AND DEPRECIATION   Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.

STOCK-BASED COMPENSATION   The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value.  The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS   The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

REVENUE RECOGNITION   The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.  We adopted this ASU effective January 1, 2018 on a full retrospective basis.  Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or related disclosures.  As such, prior period financial statements were not recast.   The Company’s revenues result from the sale of assembled products.  We recognize revenues when shipment occurs and at which point the customer obtains control and ownership of the goods.  Shipping costs generally are billed to customers and are included in sales.   The Company generally does not accept return of goods shipped unless it is a Company error.  The only credits provided to customers are for defective merchandise.  The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.  The costs under the warranty are expensed as incurred.   Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it’s probable the annual growth target will be achieved.  Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers.

LEASES   In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet.  Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current U.S. GAAP, while our accounting for capital leases remains substantially unchanged.   Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.  The standard became effective for us January 1, 2019.  The standard had a material impact on our balance sheets, but did not have a material impact on our income statements.  See NOTE 7 LEASES.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In June 2016, the FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities.  For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected.  For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down.  This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash.  The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820):  Disclosure Framework – Changes to the Disclosure for Fair Value Measurement.  The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. An entity is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In August 2018, the FASB issued ASU No. 2018-15 Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.  The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this ASU.  The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period, for all entities.  The amendments in this ASU should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

FAIR VALUE OF FINANCIAL INSTRUMENTS   The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.

ACCOUNTING FOR LONG-LIVED ASSETS   The Company reviews its long-lived assets for impairment at least annually or whenever the circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. As of September 30, 2019, the Company does not believe that any of its assets are impaired.

RECLASSIFICATION   Certain reclassifications have been made to conform prior period data to the current presentation.  These reclassifications had no effect on reported net income.

Property and equipment consists of the following at:    <table cellspacing="0" cellpadding="0" style="font-size: 10pt; margin-top: 0px"> <tr style="font-size: 1pt"> <td style="width: 335px"> </td> <td style="width: 9px"> </td> <td style="width: 9px"> </td> <td style="width: 115px"> </td> <td style="width: 19px"> </td> <td style="width: 9px"> </td> <td style="width: 115px"> </td> <td style="width: 9px"> </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 335px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1.33px solid; background-color: #ffffff; vertical-align: bottom; width: 125px"> September 30, 2019 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td colspan="2" style="margin-top: 0px; border-bottom: #000000 1.33px solid; background-color: #ffffff; vertical-align: bottom; width: 125px"> December 31, 2018 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 335px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 115px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 115px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 335px"> Land </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> — </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 54,030 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 335px"> Building </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 115px"> — </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 115px"> 171,094 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 335px"> Furniture, office equipment, and leasehold improvements </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 1,120,416 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 1,058,507 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 335px"> Manufacturing equipment and tooling </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> 1,309,172 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> 1,279,865 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 335px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 2,429,588 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 2,563,496 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 335px"> Less: accumulated depreciation </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> (1,792,660 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 19px"> ) </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 1px solid; background-color: #ffffff; vertical-align: bottom; width: 115px"> (1,704,715 </td> <td style="margin-top: 0px; background-color: #ffffff; vertical-align: bottom; width: 9px"> ) </td> </tr> <tr> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 335px"> Property and equipment, net </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #d9d9d9; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 636,928 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 19px">   </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #d9d9d9; vertical-align: bottom; width: 9px"> $ </td> <td style="margin-top: 0px; border-bottom: #000000 3px double; background-color: #d9d9d9; vertical-align: bottom; width: 115px"> 858,781 </td> <td style="margin-top: 0px; background-color: #d9d9d9; vertical-align: bottom; width: 9px">   </td> </tr> </table>

The components of lease expense were as follows: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="245"> </td> <td width="10"> </td> <td width="9"> </td> <td width="124"> </td> <td width="19"> </td> <td width="10"> </td> <td width="123"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="245">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="top" width="133"> Three Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="top" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="133"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="245">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="124">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="123">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="245"> Operating lease cost </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="124"> 37,922 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="123"> 111,672 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="245">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="124">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="123">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="245"> Finance lease cost: </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="124">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="123">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="245"> Amortization of right-of-use assets </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="124"> 1,061 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="123"> 3,182 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="245"> Interest on lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="124"> 47 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="123"> 178 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="245"> Total finance lease cost </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px; border-top-color: #000000; border-bottom-color: #000000; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-top-color: #000000; border-bottom-color: #000000; border-top-width: 1px; border-bottom-width: 3px; border-top-style: solid; border-bottom-style: double;" valign="bottom" width="124"> 1,108 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double;" valign="bottom" width="123"> 3,360 </td> </tr> </table>

Supplemental cash flow information related to leases was as follows: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="429"> </td> <td width="9"> </td> <td width="121"> </td> <td width="19"> </td> <td width="9"> </td> <td width="121"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="429">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="130"> Three Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="top" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="130"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="429">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="121">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="121">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="429"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="121">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="121">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="429"> Finance cash flows from finance leases </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="121"> 1,053 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="121"> 3,122 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="429"> Finance lease cost: </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="121">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="121">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="429"> Amortization of right-of-use assets </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="121"> 1,061 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="121"> 3,182 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="429"> Interest on lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="121"> 47 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="121"> 178 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="429"> Total finance lease cost </td> <td style="margin-top: 0px; border-top: 1px solid #000000; border-bottom: 3px double #000000;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-top: 1px solid #000000; border-bottom: 3px double #000000;" valign="bottom" width="121"> 1,108 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 3px double #000000;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom: 3px double #000000;" valign="bottom" width="121"> 3,360 </td> </tr> </table>

Supplemental balance sheet information related to leases was as follows: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="259"> </td> <td width="9"> </td> <td width="9"> </td> <td width="119"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259">   </td> <td style="margin-top: 0px;" valign="top" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="129"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259"> Operating Leases </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="119">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Operating lease right-of-use assets </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 1px; border-bottom-style: solid; background-color: #e6e6e6;" valign="bottom" width="119"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="119">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Operating lease current liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="119"> 135,275 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259"> Operating lease long term liabilities </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="119"> 271,679 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Total operating lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="119"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="119">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259"> Finance Leases </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="119">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Property and equipment, at cost </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="119"> 6,363 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259"> Accumulated depreciation </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="119"> 3,182 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Property and equipment, net </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="119"> 3,181 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="119">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Finance lease current liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="119"> 3,242 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="259"> Finance lease long term liabilities </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="119"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="259"> Total finance lease liabilities </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="119"> 3,242 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> </table>   <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="268"> </td> <td width="9"> </td> <td width="120"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="268">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="120"> Nine Months Ended September 30, 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="268"> Weighted Average Remaining Lease Term </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="120">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="268"> Operating leases </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="120"> 3 Years </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="268"> Finance leases </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="120"> 1 Year </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="268">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="120">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="268"> Weighted Average Discount Rate </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="120">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="268"> Operating leases </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="120"> 4.75% </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="268"> Finance leases </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="120"> 4.75% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> </table>

Maturities of lease liabilities are as follows:   <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="187"> </td> <td width="9"> </td> <td width="9"> </td> <td width="105"> </td> <td width="19"> </td> <td width="9"> </td> <td width="105"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="187"> Year Ending December 31, </td> <td style="margin-top: 0px;" valign="top" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="115"> Operating Leases </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="115"> Finance Leases </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="187"> 2019 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> 37,922 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> 1,100 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="187"> 2020 </td> <td style="margin-top: 0px;" valign="top" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="105"> 151,685 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="105"> 2,206 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="187"> 2021 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> 149,476 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="187"> 2022 </td> <td style="margin-top: 0px;" valign="top" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="105"> 97,256 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="105"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="187"> Total lease payments </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> 436,339 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="105"> 3,306 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="187"> Less imputed interest </td> <td style="margin-top: 0px;" valign="top" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="105"> (29,385 </td> <td style="margin-top: 0px;" valign="bottom" width="19"> ) </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="105"> (64 </td> <td style="margin-top: 0px;" valign="bottom" width="9"> ) </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="187"> Total </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="105"> 406,954 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; border-bottom-color: #000000; border-bottom-width: 3px; border-bottom-style: double; background-color: #e6e6e6;" valign="bottom" width="105"> 3,242 </td> </tr> </table>

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="201"> </td> <td width="9"> </td> <td width="9"> </td> <td width="86"> </td> <td width="19"> </td> <td width="9"> </td> <td width="86"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px;" width="201">   </td> <td style="margin-top: 0px;" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" width="211"> September 30, </td> <td style="margin-top: 0px;" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="96"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Dividend yield </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected Volatility </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 56.1 – 60.7% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 62.8 – 65.2% </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Weighted-average volatility </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected dividends </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Expected term (in years) </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 5 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Risk-free rate </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 1.60 – 2.72% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 2.80 – 2.90% </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> </table>

The following table summarizes the status of the Plan with respect to time based stock options: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="301"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="10" valign="bottom" width="399"> Nine months Ended September 30, </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="4" valign="bottom" width="179"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" valign="bottom" width="189"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="69"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="78"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="78">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at January 1 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 2,419,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.00 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,038,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Granted </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,650,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.92 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,018,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.23 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Exercised </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 160,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.37 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 125,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Forfeited </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 12,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.87 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 12,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.87 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at September 30 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 3,897,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,919,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 0.85 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Options exercisable at September 30 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,037,885 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.81 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 666,969 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 0.40 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="301"> Weighted average fair value of options granted during the period </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 1.33 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 0.68 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Stock-based compensation expense </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 473,139 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 51,592 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> </table>

The following table presents information pertaining to options outstanding at September 30, 2019:   <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="174"> </td> <td width="11"> </td> <td width="86"> </td> <td width="19"> </td> <td width="86"> </td> <td width="18"> </td> <td width="10"> </td> <td width="84"> </td> <td width="18"> </td> <td width="86"> </td> <td width="19"> </td> <td width="11"> </td> <td width="84"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="174"> Range of Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Outstanding </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Weighted Average Remaining Contractual Life </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="94"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Exercisable </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="174">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="174"> $ 0.38 – 3.15 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 3,897,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 7 years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 1.41 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 1,037,885 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 0.81 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> </table>

1517927

92266

217821

6000

508900

51250

250000

0.0173 0.0225 0.0185 2019-05-31

106700

9045

1292

99378

36264

33126

39165 37863 13749 12431

2429588

2563496

54030

171094

1120416

1058507

1309172

1279865

1792660

1704715

218328

202975

69740

68991

200000

1500000

100000 16000 1500

0.0000

0.589

0.561

0.607

0.628

0.652

P10Y

P5Y

P10Y

0.0207

0.0160

0.0272

0.0280

0.0290

2419000

3897000

1038000

1919000

1000000

1650000

1018000

1000000

1650000

90604

Paid quarterly half in cash and half in common stock

a performance bonus in the amount of $270,000 to be paid half in cash and half in stock

25000

50000

10000

2802411

994925

P42M

P31M

506729

139569

58900

51250

30022

30664

1500000

Interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. Collateralization was released on Sep. 25, 2018.

111672

37922

P3Y

P1Y

0.0475

37922

151685

149476

97256

436339

29385

1100

2206

P1Y

P3Y

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="201"> </td> <td width="9"> </td> <td width="9"> </td> <td width="86"> </td> <td width="19"> </td> <td width="9"> </td> <td width="86"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px;" width="201">   </td> <td style="margin-top: 0px;" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" width="211"> September 30, </td> <td style="margin-top: 0px;" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="96"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Dividend yield </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 0.00% </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected Volatility </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 58.9% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Weighted-average volatility </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Expected dividends </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="201"> Expected term (in years) </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 Years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="201"> Risk-free rate </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> 2.07% </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> </table>

Common stock, $0.01 par value false

The following table summarizes the status of the Plan with respect to performance based stock options: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="301"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="31"> </td> <td width="9"> </td> <td width="69"> </td> <td width="9"> </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="10" valign="bottom" width="399"> Nine months Ended September 30, </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="4" valign="bottom" width="179"> 2019 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="5" valign="bottom" width="189"> 2018 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="69"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="78"> Shares </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="79"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="78">   </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" colspan="2" valign="bottom" width="79">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at January 1 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Granted </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1,000,000 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 1.70 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Exercised </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="top" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Forfeited </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="top" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="301"> Outstanding at September 30 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1,000,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> 1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Options exercisable at September 30 </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="301"> Weighted average fair value of options granted during the period </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> 1.16 </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="31">   </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px; background-color: #e0e0e0;" valign="bottom" width="9">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="301"> Stock-based compensation expense </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> 167,636 </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="31">   </td> <td style="margin-top: 0px;" valign="bottom" width="9"> $ </td> <td style="margin-top: 0px;" valign="bottom" width="69"> — </td> <td style="margin-top: 0px;" valign="bottom" width="9">   </td> </tr> </table>

The following table presents information pertaining to performance based options outstanding at September 30, 2019: <table style="font-size: 10pt; margin-top: 0px;" cellspacing="0" cellpadding="0"> <tr style="font-size: 1pt;"> <td width="174"> </td> <td width="11"> </td> <td width="86"> </td> <td width="19"> </td> <td width="86"> </td> <td width="18"> </td> <td width="10"> </td> <td width="84"> </td> <td width="18"> </td> <td width="86"> </td> <td width="19"> </td> <td width="11"> </td> <td width="84"> </td> <td width="10"> </td> </tr> <tr> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="174"> Range of Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Outstanding </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Weighted Average Remaining Contractual Life </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="94"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" valign="bottom" width="86"> Number Exercisable </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; border-bottom: 1px solid #000000;" colspan="2" valign="bottom" width="95"> Weighted Average Exercise Price </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px;" valign="bottom" width="174">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="18">   </td> <td style="margin-top: 0px;" valign="bottom" width="86">   </td> <td style="margin-top: 0px;" valign="bottom" width="19">   </td> <td style="margin-top: 0px;" valign="bottom" width="11">   </td> <td style="margin-top: 0px;" valign="bottom" width="84">   </td> <td style="margin-top: 0px;" valign="bottom" width="10">   </td> </tr> <tr> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="174"> $1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 1,000,000 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> 10 years </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> 1.70 </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="18">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="86"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="19">   </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="11"> $ </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="84"> — </td> <td style="margin-top: 0px; background-color: #e6e6e6;" valign="bottom" width="10">   </td> </tr> </table>

NOTE 1  NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   NATURE OF OPERATIONS   REPRO MED SYSTEMS, INC. (the “Company”, “KORU Medical” or “we”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management.  The Company operates as one segment.   FISCAL YEAR END   The Company’s fiscal year end is December 31.   BASIS OF PRESENTATION   The accompanying unaudited financial statements as of September 30, 2019, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.   In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of September 30, 2019, and the results of operations and cash flow for the three and nine month periods ended September 30, 2019, and 2018.   The results of operations for the nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for the full year.  These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the twelve months ended December 31, 2018, as filed with the Securities and Exchange Commission on Form 10-K.   CASH AND CASH EQUIVALENTS   For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents.   The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.   CERTIFICATES OF DEPOSIT   The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019, at which time the funds were moved into a money market account earning interest at 2.25%.  Effective September 24, 2019, the money market account interest rate dropped to 1.85%.   INVENTORY   Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.   PATENTS   Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.   INCOME TAXES   Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences.   The Company believes that it has no uncertain tax positions requiring disclosure or adjustment.  Generally, tax years starting with 2016 are subject to examination by income tax authorities.   PROPERTY, EQUIPMENT, AND DEPRECIATION   Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.   STOCK-BASED COMPENSATION   The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value.  The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date.   USE OF ESTIMATES IN THE FINANCIAL STATEMENTS   The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.   REVENUE RECOGNITION   The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers.  We adopted this ASU effective January 1, 2018 on a full retrospective basis.  Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or related disclosures.  As such, prior period financial statements were not recast.   The Company’s revenues result from the sale of assembled products.  We recognize revenues when shipment occurs and at which point the customer obtains control and ownership of the goods.  Shipping costs generally are billed to customers and are included in sales.   The Company generally does not accept return of goods shipped unless it is a Company error.  The only credits provided to customers are for defective merchandise.  The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation.  The costs under the warranty are expensed as incurred.   Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it’s probable the annual growth target will be achieved.  Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers.   LEASES   In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet.  Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current U.S. GAAP, while our accounting for capital leases remains substantially unchanged.   Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.  The standard became effective for us January 1, 2019.  The standard had a material impact on our balance sheets, but did not have a material impact on our income statements.  See NOTE 7 LEASES.   RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In June 2016, the FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities.  For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected.  For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down.  This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash.  The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820):  Disclosure Framework – Changes to the Disclosure for Fair Value Measurement.  The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. An entity is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In August 2018, the FASB issued ASU No. 2018-15 Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.  The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this ASU.  The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period, for all entities.  The amendments in this ASU should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.   FAIR VALUE OF FINANCIAL INSTRUMENTS   The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.   ACCOUNTING FOR LONG-LIVED ASSETS   The Company reviews its long-lived assets for impairment at least annually or whenever the circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. As of September 30, 2019, the Company does not believe that any of its assets are impaired.   RECLASSIFICATION   Certain reclassifications have been made to conform prior period data to the current presentation.  These reclassifications had no effect on reported net income.

11042 12088 39501870

2481471

592787

864009

286487

36609

37500

273846

239581

0.01

75000000

42228658

40932911

39491427

38195680

2737231

406954

135275

271679

406954

6363

3182

3181

3242

3122

1053

3182

1061

178

3360

1108

NOTE 8  SUBSEQUENT EVENTS   On September 30, 2019, R. John Fletcher was appointed Chairman of the Board. Mr. Fletcher succeeds Daniel S. Goldberger who resigned as Executive Chairman of the Company in connection with his appointment as Chief Executive Officer of a bioelectronic medical device company. Mr. Goldberger remains with KORU Medical as a non-executive member of the Board of Directors. In Mr. Fletcher’s role as Chairman, he will receive an additional $50,000 in annual compensation, to be paid quarterly in shares of KORU Medical common stock based on the closing price of the stock on the last day of each quarter.   On October 14, 2019, KORU Medical announced that its common stock was approved for listing on The Nasdaq Capital Market and began trading on October 17, 2019 under its then current symbol “REPR”.   On October 23, 2019, the Company announced it will operate under a new dba name, KORU Medical Systems, in place of RMS Medical Products.   Reflecting this change, the Company’s common stock commenced trading under the new ticker symbol “KRMD” effective October 24, 2019.

2300000

1160000

P10Y

P7Y

160000

125000

12000

1037885

666969

1.00

1.41

0.41

0.85

1.70

1.92

1.23

1.70

0.37

0.41

0.87

0.81

0.40

1.33

0.68

1.16

473139

51592

167636

3897000

1000000

1.41

1.70

1037885

0.81

50000 KRMD

NOTE 4  LEGAL PROCEEDINGS   We are involved in several lawsuits with our principal competitor, EMED Technologies Corporation (“EMED”).  EMED has alleged that our needle sets infringe various patents controlled by EMED.  Certain of these lawsuits also allege antitrust violations, unfair business practices, and various other business tort claims.  We are vigorously defending against all of the lawsuits brought by EMED. Although no assurances can be given, we believe we have meritorious defenses to all of EMED’s claims.   The initial case involving EMED was filed by us in the United States District Court for the Eastern District of California on September 20, 2013 (the “California case”), in response to a letter from EMED claiming patent infringement by us, and seeking a declaratory judgment establishing the invalidity of the patent referenced in the letter – EMED’s US patent 8,500,703 – “‘703.”  EMED answered the complaint and asserted patent infringement of the ‘703 patent and several counterclaims relating generally to claims of unfair business practices against us. We responded by adding several claims against EMED, generally relating to claims of unfair business practices on EMED’s part.  Both parties have requested injunctive relief and monetary damages in unspecified amounts.  On June 16, 2015, the California court entered a preliminary injunction against KORU Medical making certain statements regarding what products were cleared by the FDA for use, or could be safely used, with KORU Medical’s Freedom60 pump, without voiding the product warranty.  On September 11, 2015, we requested an ex parte reexamination of the ‘703 patent by the US Patent and Trademark Office (“USPTO”). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017 rejecting all of EMED’s claims in the patent.  On January 25, 2018, EMED filed an Appeal Brief with a Petition for Revival, which was accepted.  On April 9, 2018, the USPTO denied EMED’s request for reconsideration of the order rejecting all claims in the ‘703 patent.  On June 26, 2019, the Examiner responded to EMED’s appeal brief and maintained all of the final rejections.  Both the California case and EMED’s appeal of the USPTO rejections are pending.   The second court case was filed by EMED in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement on another of its patents (US 8,961,476 – “‘476”), by our needle sets, and seeking unspecified monetary damages (“ED Texas ‘476 matter”). This ‘476 patent is related to the now rejected EMED ‘703 patent.   On September 17, 2015, we requested an inter partes review (“IPR”) of the ‘476 patent, and in response to our request, the Court entered an order staying the ED Texas ‘476 matter until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent.  On January 12, 2017, the PTAB issued its Final Written Decision in our favor, invalidating all but one (“dependent Claim 9”) of the claims in the ‘476 patent.   EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in our favor on April 3, 2018.  On April 18, 2018, EMED filed a petition for en banc rehearing, which was denied.  On August 16, 2018, EMED petitioned the United States Supreme Court for a Writ of Certiorari to review the Federal Circuit’s upholding the PTAB’s Final Written Decision.  On October 29, 2018 the United States Supreme Court denied EMED’s Petition for a Writ of Certiorari, thus finally affirming the PTAB’s invalidation of ‘476, save for one dependent claim.   Following the PTAB’s Final Written Decision in the IPR regarding the ‘476 patent, EMED filed a new patent application claiming priority back to the application that issued as ‘703, which is the patent at issue in the California case.  Submitted for accelerated examination, this new application issued as US 9,808,576 – “‘576” on November 7, 2017.  On this same date, EMED filed a new case (the “third case”) in the United States District Court for the Eastern District of Texas claiming patent infringement of ‘576, also directed to our needle sets, and seeking unspecified damages and a preliminary injunction against marketing and sales of our needle sets.  We filed a Motion to Dismiss or Transfer Venue to the United States District Court for the Southern District of New York (“SDNY”), which resulted in the transfer of the third case to SDNY (“SDNY ‘576 matter”) on May 30, 2018.   On April 23, 2018, EMED filed a new civil case (the “fourth case”) against us in the United States District Court for the Eastern District of Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the California case, described above.  The fourth case also names Andrew Sealfon, then President and CEO of KORU Medical, individually as a defendant.  As the result of a hearing on November 14, 2018, on December 7, 2018, the Court entered an order transferring the fourth case to the United States District Court for the Eastern District of California (the “California Court”).  The California Court set an initial schedule for a preliminary motion phase and on August 30, 2019 EMED filed a second amended complaint.  On September 30, 2019, KORU Medical and Sealfon filed a motion to dismiss that complaint, and Sealfon filed a separate motion to dismiss the case as to him for lack of jurisdiction.  Ultimately, we expect this case to be coordinated or consolidated with the California case, or dismissed, as the California Court sees fit.   At the same hearing on November 14, 2018, the Texas Court granted EMED leave to amend its infringement contentions, following the IPR decision invalidating all but one claim of the ‘476 patent, in order to assert infringement of that sole remaining claim, namely dependent Claim 9.  The Texas Court’s order allowing EMED’s amendment of its infringement contentions against us was entered on December 7, 2018.   The ED Texas ‘476 matter proceeded under EMED’s amended infringement contention to incorporate the surviving dependent Claim 9, which incorporates Claims 1 and 8 of the ‘476 patent, meaning that, to prove infringement on the part of us, EMED must prove more elements of infringement than it originally charged against us.  In April 2019, EMED served its damages expert’s report opining that EMED’s past infringement damages amount to $1.5 million, and in May KORU Medical served its damages expert’s rebuttal report opining that EMED’s expert miscalculated damages which if properly calculated would amount to less than $100,000.  The Texas Court had set a trial date of August 19, 2019, for the trial of the ED Texas ‘476 matter.  On June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision finding no infringement, literally or under the doctrine of equivalents, by KORU Medical’s accused products.  EMED filed its objections on June 26, 2019.  On June 28, 2019 the United States District Judge for the Eastern District of Texas issued a Final Judgment in favor of KORU Medical and adopted the decision of the Magistrate Judge that was issued on June 24, 2019, overruled EMED’s objections, awarded court costs to KORU Medical, and dismissed the case. A final judgment has been entered.  KORU Medical has submitted its Bill of Costs for approximately $16,000 and moved to declare the case exceptional and for recovery of its attorney fees and expenses of approximately $2.3 million in defense of EMED’s assertion of the ‘476 Patent.  EMED has objected to our Bill of Costs, opposed the motion for fees, and filed a notice of appeal of the non-infringement judgment to the Court of Appeals for the Federal Circuit.  On September 16, 2019, EMED filed its opening appeal brief.  KORU Medical plans to oppose EMED’s appeal.  The ED Texas court has stayed proceedings in the district court until the appeal process is completed.  KORU Medical’s fee motion remains pending lifting of the stay.   The SDNY ‘576 matter proceeded in the New York court through claim construction on the ‘576 Patent, whereupon KORU Medical sought permission from the New York court to file a motion for summary judgement, to which EMED objected.  The New York court granted KORU Medical’s request, and on July 10, 2019, KORU Medical filed its motion for summary judgement.  EMED opposed that motion, and on August 30, 2019, the New York court granted summary judgement, and dismissed the lawsuit.  A final judgement has been entered.  KORU Medical has submitted a Bill of Costs for approximately $1,500, to which EMED has objected, and has moved the New York court to declare the case exceptional and for recovery of its attorney fees and expenses of at least $1.16 million.  EMED has opposed that motion, which is now fully briefed and has been referred to a United States District Court Magistrate Judge to prepare a report and recommendation.  EMED also has appealed the New York court’s judgment of non-infringement to the Court of Appeals of the Federal Circuit, which matter is pending.  EMED’s opening appeal brief is currently due November 8, 2019.   As is required by the respective Courts in both the SDNY ‘576 matter and the ED Texas ‘476 matter, the parties are engaging in settlement discussions and have conducted a court-sponsored mediation session, which did not result in settlement.   Although we believe KORU Medical has meritorious claims and defenses in all of the above-described actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against us are successful, they could have a material adverse effect on our business, results of operations, financial condition and cash flows.

3306

-64

EX-101.SCH 7 krmd-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - DEBT OBLIGATIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - LEGAL PROCEEDINGS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - STOCK-BASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCK-BASED COMPENSATION (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCK-BASED COMPENSATION (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - DEBT OBLIGATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LEASES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - LEASES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - LEASES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - LEASES (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 krmd-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 krmd-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 krmd-20190930_lab.xml XBRL LABEL FILE Cash and Cash Equivalents [Axis] Certificates Of Deposit [Member] Money Market Funds [Member] Lease Arrangement, Type [Axis] Lease Agreement [Member] Property, Plant and Equipment, Type [Axis] Building [Member] Related Party [Axis] Mr. Mark Pastreich [Member] Aircraft [Member] Mr. Andrew I. Sealfon [Member] Land [Member] Furniture Office Equipment and Leasehold Improvements [Member] Manufacturing Equipment And Tooling [Member] Legal Entity [Axis] EMED Technologies Corporation [Member] Plan Name [Axis] 2015 Stock Option Plan [Member] Award Type [Axis] Time Based Shares Options [Member] Performance Based Share Options [Member] Range [Axis] Minimum [Member] Maximum [Member] Key Employees [Member] Exercise Price Range [Axis] $ 0.38 - 3.15 [Member] $1.70 [Member] Chief Executive Officer, Mr. Goldberger [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Employment Agreement [Member] Independent Directors [Member] Lender Name [Axis] Key Bank National Association [Member] Credit Facility [Axis] Line Of Credit [Member] Title of Individual [Axis] Mr Fletcher [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Incorporation, State or Country Code Entity File Number Title of 12(b) Security Trading Symbol Entity Reporting Status Current Entity Interactive Data Current Entity Small Business Entity Filer Category Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Certificates of deposit Accounts receivable less allowance for doubtful accounts of $36,609 at September 30, 2019 and $37,500 at December 31, 2018 Inventory Prepaid expenses TOTAL CURRENT ASSETS Property and equipment, net Patents, net of accumulated amortization of $273,846 and $239,581 at September 30, 2019 and December 31, 2018, respectively Right of use assets, net Deferred tax asset Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Deferred capital gain - current Accounts payable Accrued expenses Accrued payroll and related taxes Accrued tax liability Finance lease liability - current Operating lease liability - current TOTAL CURRENT LIABILITIES Deferred tax liability Operating lease liability, net of current portion TOTAL LIABILITIES STOCKHOLDERS' EQUITY Common stock, $0.01 par value; 75,000,000 shares authorized, 42,228,658 and 40,932,911 shares issued, 39,491,427 and 38,195,680 shares outstanding at September 30, 2019 and December 31, 2018, respectively Additional paid-in capital Retained earnings TOTAL STOCKHOLDERS' EQUITY BEFORE TREASURY STOCK Less: Treasury stock, 2,737,231 shares at September 30, 2019 and December 31, 2018, respectively, at cost TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Accounts receivable, allowance for doubtful accounts Patents, accumulated amortization Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Treasury stock Income Statement [Abstract] NET SALES Cost of goods sold Gross Profit OPERATING EXPENSES Selling, general and administrative Litigation Research and development Depreciation and amortization Total Operating Expenses Net Operating Profit Non-Operating Income/(Expense) Loss on currency exchange Gain on disposal of fixed asset, net Interest, net and other income, net TOTAL OTHER INCOME INCOME BEFORE TAXES Income Tax Expense NET INCOME NET INCOME PER SHARE Basic (in dollars per share) Diluted (in dollars per share) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic (in shares) Diluted (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Income Adjustments to reconcile net income to net cash (used in)/provided by operating activities: Stock based compensation expense Deferred capital gain - building lease Deferred taxes Gain on disposal of fixed asset Changes in operating assets and liabilities: (Increase)/Decrease in accounts receivable Increase in inventory Increase in prepaid expense and other assets Increase in accounts payable Decrease in accrued payroll and related taxes Increase/(Decrease) in accrued expense Decrease in accrued tax liability NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Payments for capital expenditures Purchase of certificate of deposit Payments for patents Proceeds on disposal of fixed asset Proceeds from certificates of deposit NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Stock issuances Payment for cancelled shares Finance lease NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD Supplemental Information Cash paid during the periods for: Interest Taxes NON-CASH FINANCING AND INVESTING ACTIVITIES Issuance of common stock as compensation Accounting Policies [Abstract] NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Commitments and Contingencies Disclosure [Abstract] LEGAL PROCEEDINGS Share-based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Debt Disclosure [Abstract] DEBT OBLIGATIONS Leases [Abstract] LEASES Subsequent Events [Abstract] SUBSEQUENT EVENTS NATURE OF OPERATIONS FISCAL YEAR END BASIS OF PRESENTATION CASH AND CASH EQUIVALENTS CERTIFICATES OF DEPOSIT INVENTORY PATENTS INCOME TAXES PROPERTY, EQUIPMENT, AND DEPRECIATION STOCK-BASED COMPENSATION USE OF ESTIMATES IN THE FINANCIAL STATEMENTS REVENUE RECOGNITION EX-101.PRE 11 krmd-20190930_pre.xml XBRL PRESENTATION FILE XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 5,129,028	$ 3,738,803
Certificates of deposit		1,517,927
Accounts receivable less allowance for doubtful accounts of $36,609 at September 30, 2019 and $37,500 at December 31, 2018	3,546,634	1,425,854
Inventory	2,738,682	2,103,879
Prepaid expenses	453,151	246,591
TOTAL CURRENT ASSETS	11,867,495	9,033,054
Property and equipment, net	636,928	858,781
Patents, net of accumulated amortization of $273,846 and $239,581 at September 30, 2019 and December 31, 2018, respectively	786,164	632,156
Right of use assets, net	406,954
Deferred tax asset		1,466
Other assets	19,582	19,582
TOTAL ASSETS	13,717,123	10,545,039
CURRENT LIABILITIES
Deferred capital gain - current		3,763
Accounts payable	874,977	453,498
Accrued expenses	1,178,702	688,649
Accrued payroll and related taxes	111,359	421,714
Accrued tax liability		16,608
Finance lease liability - current	3,242
Operating lease liability - current	135,275
TOTAL CURRENT LIABILITIES	2,303,555	1,584,232
Deferred tax liability	133,097
Operating lease liability, net of current portion	271,679
TOTAL LIABILITIES	2,708,331	1,584,232
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 42,228,658 and 40,932,911 shares issued, 39,491,427 and 38,195,680 shares outstanding at September 30, 2019 and December 31, 2018, respectively	422,286	409,329
Additional paid-in capital	5,985,636	4,595,214
Retained earnings	4,945,074	4,300,468
TOTAL STOCKHOLDERS' EQUITY BEFORE TREASURY STOCK	11,352,996	9,305,011
Less: Treasury stock, 2,737,231 shares at September 30, 2019 and December 31, 2018, respectively, at cost	(344,204)	(344,204)
TOTAL STOCKHOLDERS' EQUITY	11,008,792	8,960,807
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 13,717,123	$ 10,545,039

XML 13 R6.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

FISCAL YEAR END

The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION

CASH AND CASH EQUIVALENTS

CERTIFICATES OF DEPOSIT

INVENTORY

PATENTS

Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.

INCOME TAXES

The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2016 are subject to examination by income tax authorities.

PROPERTY, EQUIPMENT, AND DEPRECIATION

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.

STOCK-BASED COMPENSATION

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

REVENUE RECOGNITION

LEASES

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.

ACCOUNTING FOR LONG-LIVED ASSETS

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

XML 14 R16.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of fair value of the stock options granted Black-Scholes option valuation model

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.


	September 30,
	2019		2018

Dividend yield		0.00%		0.00%
Expected Volatility		56.1 – 60.7%		62.8 – 65.2%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10 Years		5 Years
Risk-free rate		1.60 – 2.72%		2.80 – 2.90%

Schedule of stock option plan

The following table summarizes the status of the Plan with respect to time based stock options:


	Nine months Ended September 30,
	2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	2,419,000	$	1.00		1,038,000	$	0.41
Granted	1,650,000	$	1.92		1,018,000	$	1.23
Exercised	160,000	$	0.37		125,000	$	0.41
Forfeited	12,000	$	0.87		12,000	$	0.87
Outstanding at September 30	3,897,000	$	1.41		1,919,000	$	0.85
Options exercisable at September 30	1,037,885	$	0.81		666,969	$	0.40
Weighted average fair value of options granted during the period	—	$	1.33		—	$	0.68
Stock-based compensation expense		$	473,139		—	$	51,592

Schedule of information pertaining to time based options outstanding

The following table presents information pertaining to options outstanding at September 30, 2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$ 0.38 – 3.15	3,897,000	7 years	$	1.41	1,037,885	$	0.81

Schedule of performance base share options

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.


	September 30,
	2019		2018

Dividend yield		0.00%		—
Expected Volatility		58.9%		—
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10 Years		—
Risk-free rate		2.07%		—

Schedule of performance base options outstanding

The following table summarizes the status of the Plan with respect to performance based stock options:


	Nine months Ended September 30,
	2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	—	$	—		—	$	—
Granted	1,000,000	$	1.70		—	$	—
Exercised	—	$	—		—	$	—
Forfeited	—	$	—		—	$	—
Outstanding at September 30	1,000,000	$	1.70		—	$	—
Options exercisable at September 30	—	$	—		—	$	—
Weighted average fair value of options granted during the period	—	$	1.16		—	$	—
Stock-based compensation expense	—	$	167,636		—	$	—

Schedule of information pertaining to performance base options outstanding

The following table presents information pertaining to performance based options outstanding at September 30, 2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.70	1,000,000	10 years	$	1.70	—	$	—

XML 15 R12.htm IDEA: XBRL DOCUMENT

LEASES

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

LEASES

NOTE 7 LEASES

The components of lease expense were as follows:


	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019

Operating lease cost	$	37,922	$	111,672

Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	3,182
Interest on lease liabilities		47		178
Total finance lease cost	$	1,108	$	3,360

Supplemental cash flow information related to leases was as follows:


	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019

Cash paid for amounts included in the measurement of lease liabilities:
Finance cash flows from finance leases	$	1,053	$	3,122
Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	3,182
Interest on lease liabilities		47		178
Total finance lease cost	$	1,108	$	3,360

Supplemental balance sheet information related to leases was as follows:


	Nine Months Ended September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	406,954

Operating lease current liabilities		135,275
Operating lease long term liabilities		271,679
Total operating lease liabilities	$	406,954

Finance Leases
Property and equipment, at cost	$	6,363
Accumulated depreciation		3,182
Property and equipment, net	$	3,181

Finance lease current liabilities		3,242
Finance lease long term liabilities		—
Total finance lease liabilities	$	3,242


		Nine Months Ended September 30, 2019
Weighted Average Remaining Lease Term
Operating leases		3 Years
Finance leases		1 Year

Weighted Average Discount Rate
Operating leases		4.75%
Finance leases		4.75%

Maturities of lease liabilities are as follows:


Year Ending December 31,	Operating Leases			Finance Leases
2019	$	37,922		$	1,100
2020		151,685			2,206
2021		149,476			—
2022		97,256			—
Total lease payments		436,339			3,306
Less imputed interest		(29,385	)		(64	)
Total	$	406,954		$	3,242

XML 16 R31.htm IDEA: XBRL DOCUMENT

LEASES (Details) - USD ($)	3 Months Ended	9 Months Ended
LEASES (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 37,922	$ 111,672
Finance lease cost:
Amortization of right-of-use assets	1,061	3,182
Interest on lease liabilities	47	178
Total finance lease cost	$ 1,108	$ 3,360

XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 64 292 1 false 25 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://korumedical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://korumedical.com/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://korumedical.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://korumedical.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://korumedical.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 00000007 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://korumedical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 7 false false R8.htm 00000008 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://korumedical.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 8 false false R9.htm 00000009 - Disclosure - LEGAL PROCEEDINGS Sheet http://korumedical.com/role/LegalProceedings LEGAL PROCEEDINGS Notes 9 false false R10.htm 00000010 - Disclosure - STOCK-BASED COMPENSATION Sheet http://korumedical.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 10 false false R11.htm 00000011 - Disclosure - DEBT OBLIGATIONS Sheet http://korumedical.com/role/DebtObligations DEBT OBLIGATIONS Notes 11 false false R12.htm 00000012 - Disclosure - LEASES Sheet http://korumedical.com/role/Leases LEASES Notes 12 false false R13.htm 00000013 - Disclosure - SUBSEQUENT EVENTS Sheet http://korumedical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 13 false false R14.htm 00000014 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://korumedical.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://korumedical.com/role/PropertyAndEquipment 15 false false R16.htm 00000016 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://korumedical.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://korumedical.com/role/Stock-basedCompensation 16 false false R17.htm 00000017 - Disclosure - LEASES (Tables) Sheet http://korumedical.com/role/LeasesTables LEASES (Tables) Tables http://korumedical.com/role/Leases 17 false false R18.htm 00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 18 false false R19.htm 00000019 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://korumedical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://korumedical.com/role/RelatedPartyTransactions 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://korumedical.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://korumedical.com/role/PropertyAndEquipmentTables 20 false false R21.htm 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://korumedical.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://korumedical.com/role/PropertyAndEquipmentTables 21 false false R22.htm 00000022 - Disclosure - LEGAL PROCEEDINGS (Details Narrative) Sheet http://korumedical.com/role/LegalProceedingsDetailsNarrative LEGAL PROCEEDINGS (Details Narrative) Details http://korumedical.com/role/LegalProceedings 22 false false R23.htm 00000023 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://korumedical.com/role/Stock-basedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://korumedical.com/role/Stock-basedCompensationTables 23 false false R24.htm 00000024 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://korumedical.com/role/Stock-basedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://korumedical.com/role/Stock-basedCompensationTables 24 false false R25.htm 00000025 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://korumedical.com/role/Stock-basedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://korumedical.com/role/Stock-basedCompensationTables 25 false false R26.htm 00000026 - Disclosure - STOCK-BASED COMPENSATION (Details 3) Sheet http://korumedical.com/role/Stock-basedCompensationDetails3 STOCK-BASED COMPENSATION (Details 3) Details http://korumedical.com/role/Stock-basedCompensationTables 26 false false R27.htm 00000027 - Disclosure - STOCK-BASED COMPENSATION (Details 4) Sheet http://korumedical.com/role/Stock-basedCompensationDetails4 STOCK-BASED COMPENSATION (Details 4) Details http://korumedical.com/role/Stock-basedCompensationTables 27 false false R28.htm 00000028 - Disclosure - STOCK-BASED COMPENSATION (Details 5) Sheet http://korumedical.com/role/Stock-basedCompensationDetails5 STOCK-BASED COMPENSATION (Details 5) Details http://korumedical.com/role/Stock-basedCompensationTables 28 false false R29.htm 00000029 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://korumedical.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://korumedical.com/role/Stock-basedCompensationTables 29 false false R30.htm 00000030 - Disclosure - DEBT OBLIGATIONS (Details Narrative) Sheet http://korumedical.com/role/DebtObligationsDetailsNarrative DEBT OBLIGATIONS (Details Narrative) Details http://korumedical.com/role/DebtObligations 30 false false R31.htm 00000031 - Disclosure - LEASES (Details) Sheet http://korumedical.com/role/LeasesDetails LEASES (Details) Details http://korumedical.com/role/LeasesTables 31 false false R32.htm 00000032 - Disclosure - LEASES (Details 1) Sheet http://korumedical.com/role/LeasesDetails1 LEASES (Details 1) Details http://korumedical.com/role/LeasesTables 32 false false R33.htm 00000033 - Disclosure - LEASES (Details 2) Sheet http://korumedical.com/role/LeasesDetails2 LEASES (Details 2) Details http://korumedical.com/role/LeasesTables 33 false false R34.htm 00000034 - Disclosure - LEASES (Details 3) Sheet http://korumedical.com/role/LeasesDetails3 LEASES (Details 3) Details http://korumedical.com/role/LeasesTables 34 false false R35.htm 00000035 - Disclosure - LEASES (Details 4) Sheet http://korumedical.com/role/LeasesDetails4 LEASES (Details 4) Details http://korumedical.com/role/LeasesTables 35 false false R36.htm 00000036 - Disclosure - LEASES (Details Narrative) Sheet http://korumedical.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://korumedical.com/role/LeasesTables 36 false false R37.htm 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://korumedical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://korumedical.com/role/SubsequentEvents 37 false false All Reports Book All Reports krmd-20190930.xml krmd-20190930.xsd krmd-20190930_cal.xml krmd-20190930_def.xml krmd-20190930_lab.xml krmd-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 18 R35.htm IDEA: XBRL DOCUMENT

LEASES (Details 4)	Sep. 30, 2019 USD ($)
Operating leases
2019	$ 37,922
2020	151,685
2021	149,476
2022	97,256
Total lease payments	436,339
Less imputed interest	(29,385)
Total operating lease liabilities	406,954
Financing leases
2019	1,100
2020	2,206
2021
2022
Total lease payment	3,306
Less imputed interest	(64)
Total finance lease liabilities	$ 3,242

XML 19 R28.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 5) - Performance Based Share Options [Member] - 2015 Stock Option Plan [Member] - $1.70 [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Number Outstanding \| shares	1,000,000
Weighted Average Remaining Contractual Term	10 years
Weighted Average Exercise Price \| $ / shares	$ 1.70
Number Exercisable \| shares
Weighted Average Exercise Price \| $ / shares

XML 20 R24.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1) - Time Based Shares Options [Member] - 2015 Stock Option Plan [Member] - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	2,419,000	1,038,000
Granted	1,650,000	1,018,000
Exercised	160,000	125,000
Forfeited	12,000	12,000
Outstanding at ending	3,897,000	1,919,000
Options exercisable at ending	1,037,885	666,969
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 1.00	$ 0.41
Granted	1.92	1.23
Exercised	0.37	0.41
Forfeited	0.87	0.87
Outstanding at ending	1.41	0.85
Options exercisable at ending	0.81	0.40
Weighted average fair value of options granted during the period	$ 1.33	$ 0.68
Stock-based compensation expense	$ 473,139	$ 51,592

XML 21 R20.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 2,429,588	$ 2,563,496
Less: accumulated depreciation	(1,792,660)	(1,704,715)
Property and equipment, net	636,928	858,781
Manufacturing Equipment And Tooling [Member]
Property and equipment, gross	1,309,172	1,279,865
Land [Member]
Property and equipment, gross		54,030
Furniture Office Equipment and Leasehold Improvements [Member]
Property and equipment, gross	1,120,416	1,058,507
Building [Member]
Property and equipment, gross		$ 171,094

EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION (Details 2) - Time Based Shares Options [Member] - 2015 Stock Option Plan [Member] - $ 0.38 - 3.15 [Member]
9 Months Ended

Sep. 30, 2019

$ / shares

shares

Number Outstanding | shares 3,897,000

Weighted Average Remaining Contractual Term 7 years

Weighted Average Exercise Price | $ / shares $ 1.41

Number Exercisable | shares 1,037,885

Weighted Average Exercise Price | $ / shares $ 0.81

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R21.htm IDEA: XBRL DOCUMENT v3.19.3

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

May 21, 2019

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Depreciation expense $ 69,740 $ 68,991 $ 218,328 $ 202,975

Sale of house owned $ 200,000

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sale of buildings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfBuildings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R29.htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
9 Months Ended

Apr. 02, 2019

Feb. 20, 2019

Feb. 02, 2019

Jan. 02, 2019

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Independent Directors [Member]

Description of payment terms Paid quarterly half in cash and half in common stock

Annual compensation paid per director $ 25,000 $ 50,000

Annual additional compensation per board committee chair $ 10,000

Chief Executive Officer, Mr. Goldberger [Member] | Employment Agreement [Member]

Number of shares authorized to employees 90,604

Description of payment terms a performance bonus in the amount of $270,000 to be paid half in cash and half in stock

2015 Stock Option Plan [Member] | Key Employees [Member]

Number of common shares awarded 1,650,000

Performance Based Share Options [Member] | 2015 Stock Option Plan [Member]

Number of common shares awarded 1,000,000

Weighted average grant date fair value of stock options $ 1.16

Allocated stock-based compensation expense $ 167,636

Total unrecognized compensation cost $ 994,925

Weighted-average period (in years) 31 months

Total fair value of shares vested $ 0 $ 0

Number of options outstanding 1,000,000

Time Based Shares Options [Member] | 2015 Stock Option Plan [Member]

Number of common shares awarded 1,650,000 1,018,000

Weighted average grant date fair value of stock options $ 1.33 $ 0.68

Allocated stock-based compensation expense $ 473,139 $ 51,592

Total unrecognized compensation cost $ 2,802,411

Weighted-average period (in years) 42 months

Total fair value of shares vested $ 506,729 $ 139,569

Number of options outstanding 3,897,000 1,919,000 2,419,000 1,038,000

Cash received from option exercises $ 58,900 $ 51,250

Total intrinsic value of options exercised $ 30,022 $ 30,664

X

- Definition
Amount of transactions with related party during the financial reporting period.
+ References
No definition available.
+ Details

Name: krmd_RelatedPartyTransactionAmountsOfTransaction1

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The compensation expense recognized during the period pertaining to the deferred compensation arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929
+ Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919370-209981

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77911099&loc=d3e36975-112693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918703-209980

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77888430&loc=SL77919784-209982

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RelatedPartyTransactionDescriptionOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_IndependentDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerMrGoldbergerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=krmd_EmploymentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_KeyEmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 26 0001161697-19-000477-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001161697-19-000477-xbrl.zip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�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end XML 27 R3.htm IDEA: XBRL DOCUMENT v3.19.3

BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Accounts receivable, allowance for doubtful accounts $ 36,609 $ 37,500

Patents, accumulated amortization $ 273,846 $ 239,581

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, authorized 75,000,000 75,000,000

Common stock, issued 42,228,658 40,932,911

Common stock, outstanding 39,491,427 38,195,680

Treasury stock 2,737,231 2,737,231

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 28 R7.htm IDEA: XBRL DOCUMENT v3.19.3

RELATED PARTY TRANSACTIONS
9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
NOTE 2 RELATED PARTY TRANSACTIONS

LEASED AIRCRAFT

From 1992 to 2018, we leased an aircraft from AMI Aviation, Inc., of which our former President and Chief Executive Officer, Andrew Sealfon, was a majority shareholder. The lease payments were zero and $1,292 for the three months ended September 30, 2019 and 2018, respectively and zero and $9,045 for the nine months ended September 30, 2019 and 2018 respectively. Upon the termination of Mr. Sealfon as President and Chief Executive Officer on July 25, 2018, the Company ceased leasing this aircraft.

BUILDING LEASE

Mr. Pastreich, a former director, is a principal in the entity that owns the building leased by us for our corporate headquarters and manufacturing facility at 24 Carpenter Road, Chester, New York 10918. On February 28, 2019, we completed year twenty of a twenty year lease with monthly lease payments of $11,042. On November 14, 2017, we executed a lease extension, which calls for six month extensions beginning March 1, 2019 with the option to renew six times at a monthly lease amount of $12,088. The Company exercised three additional renewal options commencing September 1, 2019 through February 28, 2021.

The lease payments were $36,264 and $33,126 for the three months ended September 30, 2019 and 2018, respectively, and $106,700 and $99,378 for the nine months ended September 30, 2019 and 2018, respectively. The Company also paid property taxes in the amount of $13,749 and $12,431 for the three months ended September 30, 2019 and 2018, respectively and $39,165 and $37,863 for the nine months ended September 30, 2019 and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.3

LEASES (Tables)
9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of components of lease expense
The components of lease expense were as follows:

Three Months Ended
September 30, 2019

Nine Months Ended
September 30, 2019

Operating lease cost

$

37,922

$

111,672

Finance lease cost:

Amortization of right-of-use assets

$

1,061

$

3,182

Interest on lease liabilities

47

178

Total finance lease cost

$

1,108

$

3,360

Schedule of cash flow information related to leases
Supplemental cash flow information related to leases was as follows:

Three Months Ended
September 30, 2019

Nine Months Ended
September 30, 2019

Cash paid for amounts included in the measurement of lease liabilities:

Finance cash flows from finance leases

$

1,053

$

3,122

Finance lease cost:

Amortization of right-of-use assets

$

1,061

$

3,182

Interest on lease liabilities

47

178

Total finance lease cost

$

1,108

$

3,360

Schdeule of balance sheet information related to leases
Supplemental balance sheet information related to leases was as follows:

Nine Months Ended
September 30, 2019

Operating Leases

Operating lease right-of-use assets

$

406,954

Operating lease current liabilities

135,275

Operating lease long term liabilities

271,679

Total operating lease liabilities

$

406,954

Finance Leases

Property and equipment, at cost

$

6,363

Accumulated depreciation

3,182

Property and equipment, net

$

3,181

Finance lease current liabilities

3,242

Finance lease long term liabilities

—

Total finance lease liabilities

$

3,242

Nine Months Ended
September 30, 2019

Weighted Average Remaining Lease Term

Operating leases

3 Years

Finance leases

1 Year

Weighted Average Discount Rate

Operating leases

4.75%

Finance leases

4.75%

Schedule of maturities of lease liabilities
Maturities of lease liabilities are as follows:

Year Ending December 31,

Operating Leases

Finance Leases

2019

$

37,922

$

1,100

2020

151,685

2,206

2021

149,476

—

2022

97,256

—

Total lease payments

436,339

3,306

Less imputed interest

(29,385

)

(64

)

Total

$

406,954

$

3,242

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of income from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919372-209981

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 6A
-URI http://asc.fasb.org/extlink&oid=118952077&loc=SL77927221-108306
+ Details

Name: us-gaap_OperatingLeaseLeaseIncomeTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 1,3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12069-110248

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694
+ Details

Name: us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R13.htm IDEA: XBRL DOCUMENT v3.19.3

SUBSEQUENT EVENTS
9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
NOTE 8 SUBSEQUENT EVENTS

On September 30, 2019, R. John Fletcher was appointed Chairman of the Board. Mr. Fletcher succeeds Daniel S. Goldberger who resigned as Executive Chairman of the Company in connection with his appointment as Chief Executive Officer of a bioelectronic medical device company. Mr. Goldberger remains with KORU Medical as a non-executive member of the Board of Directors. In Mr. Fletcher’s role as Chairman, he will receive an additional $50,000 in annual compensation, to be paid quarterly in shares of KORU Medical common stock based on the closing price of the stock on the last day of each quarter.

On October 14, 2019, KORU Medical announced that its common stock was approved for listing on The Nasdaq Capital Market and began trading on October 17, 2019 under its then current symbol “REPR”.

On October 23, 2019, the Company announced it will operate under a new dba name, KORU Medical Systems, in place of RMS Medical Products. Reflecting this change, the Company’s common stock commenced trading under the new ticker symbol “KRMD” effective October 24, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R30.htm IDEA: XBRL DOCUMENT v3.19.3

DEBT OBLIGATIONS (Details Narrative)

Feb. 08, 2018

USD ($)

Description of interest rate Interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. Collateralization was released on Sep. 25, 2018.

Line Of Credit [Member] | Key Bank National Association [Member]

Promissory note amount $ 1,500,000

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityInterestRateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LineOfCreditFacilityAxis=krmd_KeyBankNationalAssociationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R34.htm IDEA: XBRL DOCUMENT v3.19.3

LEASES (Details 3)

Sep. 30, 2019

Weighted Average Remaining Lease Term

Operating leases 3 years

Finance leases 1 year

Weighted Average Discount Rate

Operating leases 4.75%

Finance leases 4.75%

X

- References
No definition available.
+ Details

Name: krmd_WeightedAverageDiscountRateAbstract

Namespace Prefix: krmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: krmd_WeightedAverageRemainingLeaseTermAbstract

Namespace Prefix: krmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Discount rate used by lessee to determine present value of finance lease payments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeFinanceLeaseDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeFinanceLeaseRenewalTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Discount rate used by lessee to determine present value of operating lease payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

XML 33 R27.htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION (Details 4) - Performance Based Share Options [Member] - 2015 Stock Option Plan [Member] - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Outstanding at beginning

Granted 1,000,000

Exercised

Forfeited

Outstanding at ending 1,000,000

Options exercisable at ending

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding at beginning

Granted 1.70

Exercised

Forfeited

Outstanding at ending 1.70

Options exercisable at ending

Weighted average fair value of options granted during the period $ 1.16

Stock-based compensation expense $ 167,636

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION (Details) - Time Based Shares Options [Member] - 2015 Stock Option Plan [Member] - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Dividend yield 0.00% 0.00%

Expected Volatility

Weighted-average volatility

Expected dividends

Expected term (in years) 10 years 5 years

Risk-free rate

Minimum [Member]

Expected Volatility 56.10% 62.80%

Risk-free rate 1.60% 2.80%

Maximum [Member]

Expected Volatility 60.70% 65.20%

Risk-free rate 2.72% 2.90%

X

- Definition
The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Rate of weighted-average expected volatility for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 06, 2019

Cover [Abstract]

Entity Registrant Name REPRO MED SYSTEMS INC

Entity Central Index Key 0000704440

Document Type 10-Q

Document Period End Date Sep. 30, 2019

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Incorporation, State or Country Code NY

Entity File Number 0-12305

Title of 12(b) Security Common stock, $0.01 par value

Trading Symbol KRMD

Entity Reporting Status Current Yes

Entity Interactive Data Current Yes

Entity Small Business true

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company false

Entity Ex Transition Period false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 39,501,870

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2019

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 37 R5.htm IDEA: XBRL DOCUMENT v3.19.3

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

CASH FLOWS FROM OPERATING ACTIVITIES

Net Income $ 644,606 $ 1,265,703

Adjustments to reconcile net income to net cash (used in)/provided by operating activities:

Stock based compensation expense 897,300 154,925

Depreciation and amortization 252,594 228,900

Deferred capital gain - building lease (3,763) (16,860)

Deferred taxes 134,563 10,834

Gain on disposal of fixed asset (49,740) (6,000)

Changes in operating assets and liabilities:

(Increase)/Decrease in accounts receivable (2,120,780) 351,319

Increase in inventory (634,803) (290,722)

Increase in prepaid expense and other assets (206,560) (177,346)

Increase in accounts payable 421,479 137,521

Decrease in accrued payroll and related taxes (310,355) (213,700)

Increase/(Decrease) in accrued expense 490,053 (30,823)

Decrease in accrued tax liability (16,608) (60,852)

NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES (502,014) 1,352,899

CASH FLOWS FROM INVESTING ACTIVITIES

Payments for capital expenditures (158,193) (188,006)

Purchase of certificate of deposit (1,500,000)

Payments for patents (188,274) (137,858)

Proceeds on disposal of fixed asset 217,821 6,000

Proceeds from certificates of deposit 1,517,927 92,266

NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES 1,389,281 (1,727,598)

CASH FLOWS FROM FINANCING ACTIVITIES

Stock issuances 508,900 51,250

Payment for cancelled shares (2,820) (1,755)

Finance lease (3,122)

NET CASH PROVIDED BY FINANCING ACTIVITIES 502,958 49,495

NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS 1,390,225 (325,204)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 3,738,803 3,974,536

CASH AND CASH EQUIVALENTS, END OF PERIOD 5,129,028 3,649,332

Cash paid during the periods for:

Interest 280

Taxes 103,465 378,000

NON-CASH FINANCING AND INVESTING ACTIVITIES

Issuance of common stock as compensation $ 256,525 $ 103,333

X

- References
No definition available.
+ Details

Name: krmd_CashPaidDuringPeriodsForAbstract

Namespace Prefix: krmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount refer to payment for cancelled shares.
+ References
No definition available.
+ Details

Name: krmd_PaymentForCancelledShares

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) and income tax credits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DeferredIncomeTaxesAndTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfRestrictedInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R9.htm IDEA: XBRL DOCUMENT v3.19.3

LEGAL PROCEEDINGS
9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

LEGAL PROCEEDINGS
NOTE 4 LEGAL PROCEEDINGS

We are involved in several lawsuits with our principal competitor, EMED Technologies Corporation (“EMED”). EMED has alleged that our needle sets infringe various patents controlled by EMED. Certain of these lawsuits also allege antitrust violations, unfair business practices, and various other business tort claims. We are vigorously defending against all of the lawsuits brought by EMED. Although no assurances can be given, we believe we have meritorious defenses to all of EMED’s claims.

The initial case involving EMED was filed by us in the United States District Court for the Eastern District of California on September 20, 2013 (the “California case”), in response to a letter from EMED claiming patent infringement by us, and seeking a declaratory judgment establishing the invalidity of the patent referenced in the letter – EMED’s US patent 8,500,703 – “‘703.” EMED answered the complaint and asserted patent infringement of the ‘703 patent and several counterclaims relating generally to claims of unfair business practices against us. We responded by adding several claims against EMED, generally relating to claims of unfair business practices on EMED’s part. Both parties have requested injunctive relief and monetary damages in unspecified amounts. On June 16, 2015, the California court entered a preliminary injunction against KORU Medical making certain statements regarding what products were cleared by the FDA for use, or could be safely used, with KORU Medical’s Freedom60 pump, without voiding the product warranty. On September 11, 2015, we requested an ex parte reexamination of the ‘703 patent by the US Patent and Trademark Office (“USPTO”). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017 rejecting all of EMED’s claims in the patent. On January 25, 2018, EMED filed an Appeal Brief with a Petition for Revival, which was accepted. On April 9, 2018, the USPTO denied EMED’s request for reconsideration of the order rejecting all claims in the ‘703 patent. On June 26, 2019, the Examiner responded to EMED’s appeal brief and maintained all of the final rejections. Both the California case and EMED’s appeal of the USPTO rejections are pending.

The second court case was filed by EMED in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement on another of its patents (US 8,961,476 – “‘476”), by our needle sets, and seeking unspecified monetary damages (“ED Texas ‘476 matter”). This ‘476 patent is related to the now rejected EMED ‘703 patent.

On September 17, 2015, we requested an inter partes review (“IPR”) of the ‘476 patent, and in response to our request, the Court entered an order staying the ED Texas ‘476 matter until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its Final Written Decision in our favor, invalidating all but one (“dependent Claim 9”) of the claims in the ‘476 patent. EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in our favor on April 3, 2018. On April 18, 2018, EMED filed a petition for en banc rehearing, which was denied. On August 16, 2018, EMED petitioned the United States Supreme Court for a Writ of Certiorari to review the Federal Circuit’s upholding the PTAB’s Final Written Decision. On October 29, 2018 the United States Supreme Court denied EMED’s Petition for a Writ of Certiorari, thus finally affirming the PTAB’s invalidation of ‘476, save for one dependent claim.

Following the PTAB’s Final Written Decision in the IPR regarding the ‘476 patent, EMED filed a new patent application claiming priority back to the application that issued as ‘703, which is the patent at issue in the California case. Submitted for accelerated examination, this new application issued as US 9,808,576 – “‘576” on November 7, 2017. On this same date, EMED filed a new case (the “third case”) in the United States District Court for the Eastern District of Texas claiming patent infringement of ‘576, also directed to our needle sets, and seeking unspecified damages and a preliminary injunction against marketing and sales of our needle sets. We filed a Motion to Dismiss or Transfer Venue to the United States District Court for the Southern District of New York (“SDNY”), which resulted in the transfer of the third case to SDNY (“SDNY ‘576 matter”) on May 30, 2018.

On April 23, 2018, EMED filed a new civil case (the “fourth case”) against us in the United States District Court for the Eastern District of Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the California case, described above. The fourth case also names Andrew Sealfon, then President and CEO of KORU Medical, individually as a defendant. As the result of a hearing on November 14, 2018, on December 7, 2018, the Court entered an order transferring the fourth case to the United States District Court for the Eastern District of California (the “California Court”). The California Court set an initial schedule for a preliminary motion phase and on August 30, 2019 EMED filed a second amended complaint. On September 30, 2019, KORU Medical and Sealfon filed a motion to dismiss that complaint, and Sealfon filed a separate motion to dismiss the case as to him for lack of jurisdiction. Ultimately, we expect this case to be coordinated or consolidated with the California case, or dismissed, as the California Court sees fit.

At the same hearing on November 14, 2018, the Texas Court granted EMED leave to amend its infringement contentions, following the IPR decision invalidating all but one claim of the ‘476 patent, in order to assert infringement of that sole remaining claim, namely dependent Claim 9. The Texas Court’s order allowing EMED’s amendment of its infringement contentions against us was entered on December 7, 2018.

The ED Texas ‘476 matter proceeded under EMED’s amended infringement contention to incorporate the surviving dependent Claim 9, which incorporates Claims 1 and 8 of the ‘476 patent, meaning that, to prove infringement on the part of us, EMED must prove more elements of infringement than it originally charged against us. In April 2019, EMED served its damages expert’s report opining that EMED’s past infringement damages amount to $1.5 million, and in May KORU Medical served its damages expert’s rebuttal report opining that EMED’s expert miscalculated damages which if properly calculated would amount to less than $100,000. The Texas Court had set a trial date of August 19, 2019, for the trial of the ED Texas ‘476 matter. On June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision finding no infringement, literally or under the doctrine of equivalents, by KORU Medical’s accused products. EMED filed its objections on June 26, 2019. On June 28, 2019 the United States District Judge for the Eastern District of Texas issued a Final Judgment in favor of KORU Medical and adopted the decision of the Magistrate Judge that was issued on June 24, 2019, overruled EMED’s objections, awarded court costs to KORU Medical, and dismissed the case. A final judgment has been entered. KORU Medical has submitted its Bill of Costs for approximately $16,000 and moved to declare the case exceptional and for recovery of its attorney fees and expenses of approximately $2.3 million in defense of EMED’s assertion of the ‘476 Patent. EMED has objected to our Bill of Costs, opposed the motion for fees, and filed a notice of appeal of the non-infringement judgment to the Court of Appeals for the Federal Circuit. On September 16, 2019, EMED filed its opening appeal brief. KORU Medical plans to oppose EMED’s appeal. The ED Texas court has stayed proceedings in the district court until the appeal process is completed. KORU Medical’s fee motion remains pending lifting of the stay.

The SDNY ‘576 matter proceeded in the New York court through claim construction on the ‘576 Patent, whereupon KORU Medical sought permission from the New York court to file a motion for summary judgement, to which EMED objected. The New York court granted KORU Medical’s request, and on July 10, 2019, KORU Medical filed its motion for summary judgement. EMED opposed that motion, and on August 30, 2019, the New York court granted summary judgement, and dismissed the lawsuit. A final judgement has been entered. KORU Medical has submitted a Bill of Costs for approximately $1,500, to which EMED has objected, and has moved the New York court to declare the case exceptional and for recovery of its attorney fees and expenses of at least $1.16 million. EMED has opposed that motion, which is now fully briefed and has been referred to a United States District Court Magistrate Judge to prepare a report and recommendation. EMED also has appealed the New York court’s judgment of non-infringement to the Court of Appeals of the Federal Circuit, which matter is pending. EMED’s opening appeal brief is currently due November 8, 2019.

As is required by the respective Courts in both the SDNY ‘576 matter and the ED Texas ‘476 matter, the parties are engaging in settlement discussions and have conducted a court-sponsored mediation session, which did not result in settlement.

Although we believe KORU Medical has meritorious claims and defenses in all of the above-described actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against us are successful, they could have a material adverse effect on our business, results of operations, financial condition and cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136
+ Details

Name: us-gaap_LegalMattersAndContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R32.htm IDEA: XBRL DOCUMENT v3.19.3

LEASES (Details 1) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2019

Cash paid for amounts included in the measurement of lease liabilities:

Finance cash flows from finance leases $ 1,053 $ 3,122

Amortization of right-of-use assets 1,061 3,182

Interest on lease liabilities 47 178

Total finance lease cost $ 1,108 $ 3,360

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of interest expense on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 40 R36.htm IDEA: XBRL DOCUMENT v3.19.3

LEASES (Details Narrative)

Sep. 30, 2019

Maximum [Member]

Operating lease, renewal term 3 years

Minimum [Member]

Operating lease, renewal term 1 year

X

- Definition
Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981
+ Details

Name: us-gaap_LessorOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R19.htm IDEA: XBRL DOCUMENT v3.19.3

RELATED PARTY TRANSACTIONS (Details Narrative) - Lease Agreement [Member] - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Mar. 01, 2019

Feb. 28, 2019

Aircraft [Member] | Mr. Andrew I. Sealfon [Member]

Lease payments $ 0 $ 1,292 $ 0 $ 9,045

Building [Member] | Mr. Mark Pastreich [Member]

Monthly lease payments $ 12,088 $ 11,042

Lease payments 36,264 33,126 106,700 99,378

Property taxes paid $ 13,749 $ 12,431 $ 39,165 $ 37,863

X

- Definition
Monthly amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.
+ References
No definition available.
+ Details

Name: krmd_PaymentsForLeasingCost

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
It refers to amount of property tax paid.
+ References
No definition available.
+ Details

Name: krmd_PropertyTaxPaid

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.
+ References
No definition available.
+ Details

Name: us-gaap_PaymentsForLeasingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=krmd_LeaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AirTransportationEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_PresidentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_Director1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R15.htm IDEA: XBRL DOCUMENT v3.19.3

PROPERTY AND EQUIPMENT (Tables)
9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of property and equipment
Property and equipment consists of the following at:

September 30, 2019

December 31, 2018

Land

$

—

$

54,030

Building

—

171,094

Furniture, office equipment, and leasehold improvements

1,120,416

1,058,507

Manufacturing equipment and tooling

1,309,172

1,279,865

2,429,588

2,563,496

Less: accumulated depreciation

(1,792,660

)

(1,704,715

)

Property and equipment, net

$

636,928

$

858,781

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R11.htm IDEA: XBRL DOCUMENT v3.19.3

DEBT OBLIGATIONS
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

DEBT OBLIGATIONS
NOTE 6 DEBT OBLIGATIONS

On February 8, 2018, the Company issued a Promissory Note to KeyBank National Association (“KeyBank”) in the amount of $1.5 million as a variable rate revolving line of credit loan due on demand with an interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. The Company entered into this arrangement to establish a credit lending history and, in the event needed, to have additional cash on hand for future expansion. On September 25, 2018, KeyBank released the certificate of deposit as collateral for the loan and the Company executed a Commercial Security Agreement as collateral for the loan. As of September 30, 2019, the Company had no outstanding amounts against the line of credit.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R8.htm IDEA: XBRL DOCUMENT v3.19.3

PROPERTY AND EQUIPMENT
9 Months Ended

Sep. 30, 2019

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT
NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:

September 30, 2019

December 31, 2018

Land

$

—

$

54,030

Building

—

171,094

Furniture, office equipment, and leasehold improvements

1,120,416

1,058,507

Manufacturing equipment and tooling

1,309,172

1,279,865

2,429,588

2,563,496

Less: accumulated depreciation

(1,792,660

)

(1,704,715

)

Property and equipment, net

$

636,928

$

858,781

On May 21, 2019, the Company sold the house it owned for $0.2 million.

Depreciation expense was $69,740 and $68,991 for the three months ended September 30, 2019 and 2018, respectively, and $218,328 and $202,975 for the nine months ended September 30, 2019 and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.19.3

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Statement [Abstract]

NET SALES $ 6,617,397 $ 4,547,187 $ 16,940,487 $ 13,082,737

Cost of goods sold 2,234,489 1,655,619 6,033,961 4,985,761

Gross Profit 4,382,908 2,891,568 10,906,526 8,096,976

OPERATING EXPENSES

Selling, general and administrative 2,441,381 1,917,127 6,976,684 5,513,727

Litigation 864,009 286,487 2,481,471 592,787

Research and development 170,260 126,923 450,454 160,735

Depreciation and amortization 82,774 78,345 252,594 228,900

Total Operating Expenses 3,558,424 2,408,882 10,161,203 6,496,149

Net Operating Profit 824,484 482,686 745,323 1,600,827

Non-Operating Income/(Expense)

Loss on currency exchange (9,358) (5,842) (20,283) (16,256)

Gain on disposal of fixed asset, net 6,000 49,740 6,000

Interest, net and other income, net 23,368 6,972 59,091 13,088

TOTAL OTHER INCOME 14,010 7,130 88,548 2,832

INCOME BEFORE TAXES 838,494 489,816 833,871 1,603,659

Income Tax Expense (186,681) (103,263) (189,265) (337,956)

NET INCOME $ 651,813 $ 386,553 $ 644,606 $ 1,265,703

NET INCOME PER SHARE

Basic (in dollars per share) $ 0.02 $ 0.01 $ 0.02 $ 0.03

Diluted (in dollars per share) $ 0.02 $ 0.01 $ 0.02 $ 0.03

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic (in shares) 39,022,298 38,194,682 38,534,021 38,104,393

Diluted (in shares) 39,298,408 38,985,684 38,734,083 38,875,737

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.19.3

LEASES (Details 2)

Sep. 30, 2019

USD ($)

Operating Leases

Operating lease right-of-use assets $ 406,954

Operating lease current liabilities 135,275

Operating lease long term liabilities 271,679

Total operating lease liabilities 406,954

Finance Leases

Property and equipment, at cost 6,363

Accumulated depreciation 3,182

Property and equipment, net 3,181

Finance lease current liabilities 3,242

Total finance lease liabilities $ 3,242

X

- References
No definition available.
+ Details

Name: krmd_AssetsAndLiabilitiesLesseeFinanceAbstract

Namespace Prefix: krmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: krmd_AssetsAndLiabilitiesOperatingLesseeAbstract

Namespace Prefix: krmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentOtherNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.3

SUBSEQUENT EVENTS (Details Narrative)
9 Months Ended

Sep. 30, 2019

USD ($)

Mr Fletcher [Member]

Additional Annual Compensation $ 50,000

X

- Definition
Amount represents value of annual compensation to be paid to chairman.
+ References
No definition available.
+ Details

Name: krmd_AdditionalAnnualCompensation

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R14.htm IDEA: XBRL DOCUMENT v3.19.3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

NATURE OF OPERATIONS
NATURE OF OPERATIONS

REPRO MED SYSTEMS, INC. (the “Company”, “KORU Medical” or “we”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management. The Company operates as one segment.

FISCAL YEAR END
FISCAL YEAR END

The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION
BASIS OF PRESENTATION

The accompanying unaudited financial statements as of September 30, 2019, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.

In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of September 30, 2019, and the results of operations and cash flow for the three and nine month periods ended September 30, 2019, and 2018.

The results of operations for the nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the twelve months ended December 31, 2018, as filed with the Securities and Exchange Commission on Form 10-K.

CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS

For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.

CERTIFICATES OF DEPOSIT
CERTIFICATES OF DEPOSIT

The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019, at which time the funds were moved into a money market account earning interest at 2.25%. Effective September 24, 2019, the money market account interest rate dropped to 1.85%.

INVENTORY
INVENTORY

Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.

PATENTS
PATENTS

Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.

INCOME TAXES
INCOME TAXES

Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences.

The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2016 are subject to examination by income tax authorities.

PROPERTY, EQUIPMENT, AND DEPRECIATION
PROPERTY, EQUIPMENT, AND DEPRECIATION

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.

STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS
USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

REVENUE RECOGNITION
REVENUE RECOGNITION

The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted this ASU effective January 1, 2018 on a full retrospective basis. Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or related disclosures. As such, prior period financial statements were not recast.

The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs and at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales.

The Company generally does not accept return of goods shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred.

Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it’s probable the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers.

LEASES
LEASES

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current U.S. GAAP, while our accounting for capital leases remains substantially unchanged. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard became effective for us January 1, 2019. The standard had a material impact on our balance sheets, but did not have a material impact on our income statements. See NOTE 7 LEASES.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure for Fair Value Measurement. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ASU. An entity is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In August 2018, the FASB issued ASU No. 2018-15 Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this ASU. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period, for all entities. The amendments in this ASU should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

FAIR VALUE OF FINANCIAL INSTRUMENTS
FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.

ACCOUNTING FOR LONG-LIVED ASSETS
ACCOUNTING FOR LONG-LIVED ASSETS

The Company reviews its long-lived assets for impairment at least annually or whenever the circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. As of September 30, 2019, the Company does not believe that any of its assets are impaired.

RECLASSIFICATION
RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

X

- Definition
Disclosure of accounting policy for short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.
+ References
No definition available.
+ Details

Name: krmd_CertificatesOfDepositPolicyTextBlock

Namespace Prefix: krmd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02(b))
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03(b))
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828
+ Details

Name: us-gaap_FiscalPeriod

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION
9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION
NOTE 5 STOCK-BASED COMPENSATION

On June 29, 2016, the Board of Directors amended the 2015 Stock Option Plan (as amended, the “Plan”) authorizing the Company to grant awards to certain executives, key employees, and consultants under the Plan, which was approved by shareholders at the Annual Meeting held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed 6,000,000 pursuant to an amendment to the Plan approved by shareholders on April 23, 2019 at the 2019 Annual Meeting of Shareholders.

As of September 30, 2019, the Company had 3,897,000 time based stock options outstanding to certain executives, key employees and consultants under the Plan, of which 1,650,000 were issued during the nine months ended September 30, 2019. The Company also had 1,000,000 performance based options outstanding under the Plan as of September 30, 2019, to its President and Chief Executive Officer, of which all were issued during the nine months ending September 30, 2019.

On February 20, 2019, the Board of Directors of the Company approved an increase in compensation for each non-employee director from $25,000 to $50,000 annually effective January 1, 2019 and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock at the end of each fiscal quarter.

Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000 to be paid half in cash and half in stock on April 1, 2019. The number of shares that were issued totaled 90,604 and was based upon the closing price of the Common Stock of the Company on February 1, 2019 as reported by the OTCQX. These shares were issued on April 3, 2019.

2015 STOCK OPTION PLAN, as amended

Time Based Stock Options

The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and September 30, 2018 was $1.33 and $0.68, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.

September 30,

2019

2018

Dividend yield

0.00%

0.00%

Expected Volatility

56.1 – 60.7%

62.8 – 65.2%

Weighted-average volatility

—

—

Expected dividends

—

—

Expected term (in years)

10 Years

5 Years

Risk-free rate

1.60 – 2.72%

2.80 – 2.90%

The following table summarizes the status of the Plan with respect to time based stock options:

Nine months Ended September 30,

2019

2018

Shares

Weighted
Average
Exercise
Price

Shares

Weighted
Average
Exercise
Price

Outstanding at January 1

2,419,000

$

1.00

1,038,000

$

0.41

Granted

1,650,000

$

1.92

1,018,000

$

1.23

Exercised

160,000

$

0.37

125,000

$

0.41

Forfeited

12,000

$

0.87

12,000

$

0.87

Outstanding at September 30

3,897,000

$

1.41

1,919,000

$

0.85

Options exercisable at September 30

1,037,885

$

0.81

666,969

$

0.40

Weighted average fair value of options granted during the period

—

$

1.33

—

$

0.68

Stock-based compensation expense

$

473,139

—

$

51,592

Total stock-based compensation expense totaled $473,139 and $51,592 for the nine months ended September 30, 2019 and 2018, respectively. Cash received from option exercises for the nine months ended September 30, 2019 and 2018 was $58,900 and $51,250, respectively.

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and 2018, was $1.33 and $0.68, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2019 and 2018, was $30,022 and $30,664, respectively.

The following table presents information pertaining to options outstanding at September 30, 2019:

Range of Exercise Price

Number
Outstanding

Weighted
Average
Remaining
Contractual
Life

Weighted
Average
Exercise
Price

Number
Exercisable

Weighted
Average
Exercise
Price

$ 0.38 – 3.15

3,897,000

7 years

$

1.41

1,037,885

$

0.81

As of September 30, 2019, there was $2,802,411 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 42 months. The total fair value of shares vested as of September 30, 2019 and 2018, was $506,729 and $139,569, respectively.

Performance Based Stock Options

The per share weighted average fair value of stock options granted during the nine months ended September 30, 2019 and 2018 was $1.16 and zero, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2019 and September 30, 2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.

September 30,

2019

2018

Dividend yield

0.00%

—

Expected Volatility

58.9%

—

Weighted-average volatility

—

—

Expected dividends

—

—

Expected term (in years)

10 Years

—

Risk-free rate

2.07%

—

The following table summarizes the status of the Plan with respect to performance based stock options:

Nine months Ended September 30,

2019

2018

Shares

Weighted
Average
Exercise
Price

Shares

Weighted
Average
Exercise
Price

Outstanding at January 1

—

$

—

—

$

—

Granted

1,000,000

$

1.70

—

$

—

Exercised

—

$

—

—

$

—

Forfeited

—

$

—

—

$

—

Outstanding at September 30

1,000,000

$

1.70

—

$

—

Options exercisable at September 30

—

$

—

—

$

—

Weighted average fair value of options granted during the period

—

$

1.16

—

$

—

Stock-based compensation expense

—

$

167,636

—

$

—

Total performance stock-based compensation expense totaled $167,636 and zero for the nine months ended September 30, 2019 and 2018, respectively.

The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2019 and September 30, 2018, was $1.16 and zero, respectively.

The following table presents information pertaining to performance based options outstanding at September 30, 2019:

Range of Exercise Price

Number
Outstanding

Weighted
Average
Remaining
Contractual
Life

Weighted
Average
Exercise
Price

Number
Exercisable

Weighted
Average
Exercise
Price

$1.70

1,000,000

10 years

$

1.70

—

$

—

As of September 30, 2019, there was $994,925 of total unrecognized compensation cost related to non-vested performance share option based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 31 months. The total fair value of shares vested as of September 30, 2019 and 2018 was zero for both periods.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R18.htm IDEA: XBRL DOCUMENT v3.19.3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
9 Months Ended

Sep. 30, 2019

USD ($)

Number

Sep. 24, 2019

Number of segments | Number 1

FDIC cash uninsured amount | $ $ 250,000

Certificate of deposit, matured date May 31, 2019

Certificates Of Deposit [Member]

Interest rate 1.73%

Money Market Funds [Member]

Interest rate 2.25% 1.85%

X

- Definition
Represent the certificate of deposit matured date.
+ References
No definition available.
+ Details

Name: krmd_CertificateOfDepositMaturedDate

Namespace Prefix: krmd_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
It refers the percentage of interest rate on certificate of deposit.
+ References
No definition available.
+ Details

Name: krmd_InterestRateOnCertificatesOfDeposit

Namespace Prefix: krmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R26.htm IDEA: XBRL DOCUMENT v3.19.3

STOCK-BASED COMPENSATION (Details 3) - Performance Based Share Options [Member] - 2015 Stock Option Plan [Member] - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Dividend yield 0.00%

Expected Volatility 58.90%

Weighted-average volatility

Expected dividends

Expected term (in years) 10 years

Risk-free rate 2.07%

X

- Definition
The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Rate of weighted-average expected volatility for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R22.htm IDEA: XBRL DOCUMENT v3.19.3

LEGAL PROCEEDINGS (Details Narrative) - EMED Technologies Corporation [Member] - USD ($)
1 Months Ended 9 Months Ended

Aug. 30, 2019

Apr. 30, 2019

Sep. 30, 2019

Past infringement damages amount $ 1,500,000

Properly damages amount $ 100,000

Bill of Costs $ 1,500 $ 16,000

Legal fees $ 1,160,000 $ 2,300,000

X

- Definition
Amount of loss contingency bill of costs.
+ References
No definition available.
+ Details

Name: krmd_LossContingencyBillOfCosts

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss contingency properly damages.
+ References
No definition available.
+ Details

Name: krmd_LossContingencyProperlyDamagesAmount

Namespace Prefix: krmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of damages awarded to the plaintiff in the legal matter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyDamagesAwardedValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=krmd_EMEDTechnologiesCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	May 21, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 69,740	$ 68,991	$ 218,328	$ 202,975
Sale of house owned	$ 200,000

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)					9 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Apr. 02, 2019	Feb. 20, 2019	Feb. 02, 2019	Jan. 02, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Independent Directors [Member]
Description of payment terms		Paid quarterly half in cash and half in common stock
Annual compensation paid per director		$ 25,000		$ 50,000
Annual additional compensation per board committee chair		$ 10,000
Chief Executive Officer, Mr. Goldberger [Member] \| Employment Agreement [Member]
Number of shares authorized to employees			90,604
Description of payment terms	a performance bonus in the amount of $270,000 to be paid half in cash and half in stock
2015 Stock Option Plan [Member] \| Key Employees [Member]
Number of common shares awarded					1,650,000
Performance Based Share Options [Member] \| 2015 Stock Option Plan [Member]
Number of common shares awarded					1,000,000
Weighted average grant date fair value of stock options					$ 1.16
Allocated stock-based compensation expense					$ 167,636
Total unrecognized compensation cost					$ 994,925
Weighted-average period (in years)					31 months
Total fair value of shares vested					$ 0	$ 0
Number of options outstanding					1,000,000
Time Based Shares Options [Member] \| 2015 Stock Option Plan [Member]
Number of common shares awarded					1,650,000	1,018,000
Weighted average grant date fair value of stock options					$ 1.33	$ 0.68
Allocated stock-based compensation expense					$ 473,139	$ 51,592
Total unrecognized compensation cost					$ 2,802,411
Weighted-average period (in years)					42 months
Total fair value of shares vested					$ 506,729	$ 139,569
Number of options outstanding					3,897,000	1,919,000	2,419,000	1,038,000
Cash received from option exercises					$ 58,900	$ 51,250
Total intrinsic value of options exercised					$ 30,022	$ 30,664

BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 36,609	$ 37,500
Patents, accumulated amortization	$ 273,846	$ 239,581
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	75,000,000	75,000,000
Common stock, issued	42,228,658	40,932,911
Common stock, outstanding	39,491,427	38,195,680
Treasury stock	2,737,231	2,737,231

DEBT OBLIGATIONS (Details Narrative)	Feb. 08, 2018 USD ($)
Description of interest rate	Interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. Collateralization was released on Sep. 25, 2018.
Line Of Credit [Member] \| Key Bank National Association [Member]
Promissory note amount	$ 1,500,000

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 06, 2019
Cover [Abstract]
Entity Registrant Name	REPRO MED SYSTEMS INC
Entity Central Index Key	0000704440
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	NY
Entity File Number	0-12305
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	KRMD
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,501,870
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$ 644,606	$ 1,265,703
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Stock based compensation expense	897,300	154,925
Depreciation and amortization	252,594	228,900
Deferred capital gain - building lease	(3,763)	(16,860)
Deferred taxes	134,563	10,834
Gain on disposal of fixed asset	(49,740)	(6,000)
Changes in operating assets and liabilities:
(Increase)/Decrease in accounts receivable	(2,120,780)	351,319
Increase in inventory	(634,803)	(290,722)
Increase in prepaid expense and other assets	(206,560)	(177,346)
Increase in accounts payable	421,479	137,521
Decrease in accrued payroll and related taxes	(310,355)	(213,700)
Increase/(Decrease) in accrued expense	490,053	(30,823)
Decrease in accrued tax liability	(16,608)	(60,852)
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES	(502,014)	1,352,899
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for capital expenditures	(158,193)	(188,006)
Purchase of certificate of deposit		(1,500,000)
Payments for patents	(188,274)	(137,858)
Proceeds on disposal of fixed asset	217,821	6,000
Proceeds from certificates of deposit	1,517,927	92,266
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	1,389,281	(1,727,598)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuances	508,900	51,250
Payment for cancelled shares	(2,820)	(1,755)
Finance lease	(3,122)
NET CASH PROVIDED BY FINANCING ACTIVITIES	502,958	49,495
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	1,390,225	(325,204)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	3,738,803	3,974,536
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,129,028	3,649,332
Cash paid during the periods for:
Interest	280
Taxes	103,465	378,000
NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$ 256,525	$ 103,333

LEASES (Details 1) - USD ($)	3 Months Ended	9 Months Ended
LEASES (Details 1) - USD ($)	Sep. 30, 2019	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Finance cash flows from finance leases	$ 1,053	$ 3,122
Amortization of right-of-use assets	1,061	3,182
Interest on lease liabilities	47	178
Total finance lease cost	$ 1,108	$ 3,360

LEASES (Details Narrative)	Sep. 30, 2019
Maximum [Member]
Operating lease, renewal term	3 years
Minimum [Member]
Operating lease, renewal term	1 year

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
NET SALES	$ 6,617,397	$ 4,547,187	$ 16,940,487	$ 13,082,737
Cost of goods sold	2,234,489	1,655,619	6,033,961	4,985,761
Gross Profit	4,382,908	2,891,568	10,906,526	8,096,976
OPERATING EXPENSES
Selling, general and administrative	2,441,381	1,917,127	6,976,684	5,513,727
Litigation	864,009	286,487	2,481,471	592,787
Research and development	170,260	126,923	450,454	160,735
Depreciation and amortization	82,774	78,345	252,594	228,900
Total Operating Expenses	3,558,424	2,408,882	10,161,203	6,496,149
Net Operating Profit	824,484	482,686	745,323	1,600,827
Non-Operating Income/(Expense)
Loss on currency exchange	(9,358)	(5,842)	(20,283)	(16,256)
Gain on disposal of fixed asset, net		6,000	49,740	6,000
Interest, net and other income, net	23,368	6,972	59,091	13,088
TOTAL OTHER INCOME	14,010	7,130	88,548	2,832
INCOME BEFORE TAXES	838,494	489,816	833,871	1,603,659
Income Tax Expense	(186,681)	(103,263)	(189,265)	(337,956)
NET INCOME	$ 651,813	$ 386,553	$ 644,606	$ 1,265,703
NET INCOME PER SHARE
Basic (in dollars per share)	$ 0.02	$ 0.01	$ 0.02	$ 0.03
Diluted (in dollars per share)	$ 0.02	$ 0.01	$ 0.02	$ 0.03
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic (in shares)	39,022,298	38,194,682	38,534,021	38,104,393
Diluted (in shares)	39,298,408	38,985,684	38,734,083	38,875,737

LEASES (Details 2)	Sep. 30, 2019 USD ($)
Operating Leases
Operating lease right-of-use assets	$ 406,954
Operating lease current liabilities	135,275
Operating lease long term liabilities	271,679
Total operating lease liabilities	406,954
Finance Leases
Property and equipment, at cost	6,363
Accumulated depreciation	3,182
Property and equipment, net	3,181
Finance lease current liabilities	3,242
Total finance lease liabilities	$ 3,242

SUBSEQUENT EVENTS (Details Narrative)	9 Months Ended
SUBSEQUENT EVENTS (Details Narrative)	Sep. 30, 2019 USD ($)
Mr Fletcher [Member]
Additional Annual Compensation	$ 50,000

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	9 Months Ended
	Sep. 30, 2019 USD ($) Number	Sep. 24, 2019
Number of segments \| Number	1
FDIC cash uninsured amount \| $	$ 250,000
Certificate of deposit, matured date	May 31, 2019
Certificates Of Deposit [Member]
Interest rate	1.73%
Money Market Funds [Member]
Interest rate	2.25%	1.85%

LEGAL PROCEEDINGS (Details Narrative) - EMED Technologies Corporation [Member] - USD ($)		1 Months Ended	9 Months Ended
	Aug. 30, 2019	Apr. 30, 2019	Sep. 30, 2019
Past infringement damages amount		$ 1,500,000
Properly damages amount		$ 100,000
Bill of Costs	$ 1,500		$ 16,000
Legal fees	$ 1,160,000		$ 2,300,000